[
    {
        "pmid": "40819221",
        "title": "Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.",
        "abstract": "study assesses incidence timing undetectable prostatespecific antigen PSA radiotherapy RT ± androgen deprivation therapy ADT association prostate cancer mortality populationbased study including 5299 men undergoing RT 20062020 Stockholm County Sweden PSA test death emigration author calculated incidence timing undetectable PSA PSA ≤01 ngmL used competing risk regression evaluate association detectable PSA 6 12 month prostate cancer mortality PCSM Median followup survivor 81 32 130 months PSA nadir value reached 6 12 month 233 23 470 36 patient undergoing RT 2871 85 3612 90 patient undergoing RTADT significant association found PSA nadir 6 12 month PCSM radiotherapy group evidence association higher PCSM RTADT group PSA nadir subdistribution hazard ratio sHR 223 201249 PSA 6 months sHR 691 517923 PSA 12 months sHR 379 230625 12 year RT  ADT PCSM rate 27 15 13 5 patient PSA 6 month ≥05 0205 0102 ≤01 ngmL respectively corresponding rate PSA 12 month 34 18 12 5 patient undergoing RTADT reached PSA ≤01 ngmL within 6 12 months PSA01 ngmL time point indicated higher risk PCSM emphasizing need timely restaging intensified salvage treatments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819221/",
        "source_type": "Global"
    },
    {
        "pmid": "40819203",
        "title": "Prevalence of Breast Edema Following Conservative Breast Therapy in Israeli Patients.",
        "abstract": "Breast edema characterized fluid accumulation breast tissue common yet understudied complication following breastconserving surgery BCS radiotherapy breast cancer impact physical emotional wellbeing highlight need deeper exploration prevalence risk factors clinical management evaluate prevalence breast edema following breast surgery investigate association arm lymphedema explore link surgical interventions analyzed 105 breast cancer patient treated BCS axillary interventions including sentinel lymph node biopsy SLNB lymph node sampling axillary lymph node dissection ALND Comprehensive evaluation included physical exams arm circumference measurements thorough review patient demographics medical history disease progression assess presence severity breast arm lymphedema Breast edema prevalence 76 rate significantly influenced surgical extent None SLNB patient exhibited breast edema compared 235 ALND patients Significant predictor included arm lymphedema OR 5754 P  0024 body mass index OR 065 P  0016 tumor grade OR 5178 P  0040 Cooccurrence breast arm lymphedema observed 50 cases Breast edema significant postoperative complication influenced surgical extent lymphatic disruption Improved diagnostic methods multidisciplinary care innovative surgical strategy essential mitigating condition enhancing patient outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819203/",
        "source_type": "Global"
    },
    {
        "pmid": "40819188",
        "title": "Human Papillomavirus Type and Viral Load in Relation to Circulating Cell-Free Tumour HPV DNA Level and Survival in Cervical Cancer.",
        "abstract": "Human papillomavirus HPV cause cervical cancer released circulating cellfree tumour HPV DNA ctHPV DNA circulation Earlier study indicated ctHPV DNA promising biomarker analysing treatment response recurrence surveillance However factor influencing release ctHPV DNA including HPV type HPV viral load extensively studied additional biomarkers prognosis needed Therefore analysed ctHPV DNA HPV type viral load relation progressionfree survival patient locally advanced advanced cervical cancer Pretreatment biopsy blood sample collected patient diagnosed cervical cancer Federation Gynecology Obstetrics FIGO stage IBIV One hundred seventeen patient HPVpositive tumour included Human papillomavirus typespecific droplet digital polymerase chain reaction ddPCR assay used analyse previously genotyped biopsy viral load Pretreatment plasma 92117 patient available analysed ctHPV DNA total cellfree DNA levels Results related patient tumour characteristic progressionfree survival Patients grouped based HPV specie alpha9species including HPV16 alpha7species including HPV 18 constituted majority cases Cellfree tumour HPV DNA found 8392 902 pretreatment plasma samples Higher biopsy viral load significantly related higher ctHPV DNA level Higher stage larger primary tumour size also associated higher ctHPV DNA level Alpha9 species including HPV16 significantly higher viral load 16× higher ctHPV DNA level 17× higher detection rate plasma alpha7 species including HPV18 Alpha9 specie also significantly better progressionfree survival alpha7 species Additional factor leading better progressionfree survival included lower stage lower total cellfree DNA level viral load 90th percentile and highrisk cervical cancer group higher pretreatment ctHPV DNA level Cellfree tumour HPV DNA HPV type viral load promising biomarkers cervical cancer lower sensitivity ctHPV DNA detection alpha7 species including HPV18 need considered future study ctHPV DNA especially used marker relapse surveillance ctHPV DNA level low",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819188/",
        "source_type": "Global"
    },
    {
        "pmid": "40819186",
        "title": "Analyzing the mechanism of rhubarb in the treatment of cervical cancer based on network pharmacology and molecular docking technology.",
        "abstract": "investigate mechanism action rhubarb treatment cervical cancer computer simulation technique network pharmacology molecular docking technology active ingredient rhubarb identified using TCMSP HERB databases active ingredient target prediction performed using SEA Swiss TargetPrediction cervical cancerrelated target collected four databases namely OMIM GeneCards CTD GDA common target drug disease obtained Draw Venn diagram STRING online platform applied build proteinprotein interaction network PPI core target important module screened cytoscape 3103 use DAVID REACTOM database perform GO functional enrichment analysis KEGG pathway enrichment analysis visualize results Finally molecular docking key active ingredient target performed PubChem database Auto Dock software result visualized PyMOL 23 active ingredient 106 common target obtained screening result GO KEGG enrichment analysis indicated rhubarb involved phosphorylation ATP binding EGFR HIF1 PI3KAKT ESRmediated signaling IL4 IL13 signaling pathway cervical cancer treatment molecular docking result showed rhubarb key active ingredient 353trihydroxy674trimethoxyflavone eupatin5carboxy7hydroxy2methylbenzopyranγone rhapontigenin chrysophanol good docking activity core target EGFR IGF1R AKT1 MMP9 MET SRC among AKT1 lowest binding energy chrysophanol indicating strongest affinity them variety active ingredient rhubarb play therapeutic role cervical cancer regulating multitargets multiple pathways among which AKT1 showed higher correlation ESRmediated signaling relevant result verified vitro vivo experiments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819186/",
        "source_type": "Global"
    },
    {
        "pmid": "40819167",
        "title": "Bridging the gap: ctDNA, genomics, and equity in breast cancer care.",
        "abstract": "Circulating tumor DNA ctDNA emerged powerful tool precision oncology offering noninvasive approach tumor profiling minimal residual disease MRD treatment monitoring breast cancer ctDNA shown promise metastatic earlystage settings However application benefit equitably realized across populations review examined current evidence ctDNA detection assay performance clinical utility specifically within racially ethnically geographically underrepresented populations synthesized data genomic studies ctDNAbased trials implementation research identify disparity ctDNA levels mutational profiles testing utilization access genotypematched therapies disparity compounded structural barrier insurance coverage geographic access limited inclusion clinical research Global data low middleincome country reinforced feasibility challenge ctDNA implementation resourceconstrained settings ctDNA hold considerable potential personalize breast cancer care finding underscore urgent need integrate equity validation clinical application policy development avoid perpetuating existing disparities",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819167/",
        "source_type": "Global"
    },
    {
        "pmid": "40819165",
        "title": "ROSIE: AI generation of multiplex immunofluorescence staining from histopathology images.",
        "abstract": "Hematoxylin eosin HE common inexpensive histopathology assay Though widely used informationrich cannot directly inform specific molecular markers require additional experiment assess address gap present ROSIE deeplearning framework computationally imputes expression localization dozen protein HE images model trained dataset 1300 paired aligned HE multiplex immunofluorescence mIF sample dozen tissue disease conditions spanning 16 million cells Validation silico mIF staining method heldout HE sample demonstrates predicted biomarkers effective identifying cell phenotypes particularly distinguishing lymphocyte B cell cells readily discernible HE staining alone Additionally ROSIE facilitates robust identification stromal epithelial microenvironments immune cell subtypes like tumorinfiltrating lymphocyte TILs important understanding tumorimmune interaction help inform treatment strategy cancer research",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819165/",
        "source_type": "Global"
    },
    {
        "pmid": "40819158",
        "title": "Preparation of cancer cell membrane-coated Gambogic acid-loaded pH-sensitive liposomes to enhance targeted anti-hepatocellular carcinoma effect.",
        "abstract": "Hepatocellular carcinoma insidious onset therefore patient already middle advanced stage diagnosed seriously affect prognosis patients long time difficult achieve expected effect treatment effectively deal middleorlate stage liver cancer Gambogic acid GA dry resin secreted Garcinia hanbaryi Hookf natural active ingredient various biological activities especially strong antihepatocellular carcinoma activity However drawback high toxicity liver kidney low solubility greatly limited application Therefore necessary develop suitable Gambogic acid formulation overcome disadvantages study injectable HepG2 cell membranemodified pHresponsive liposome PEOzGAHepG2m prepared active targeted delivery Gambogic acid treatment hepatocellular carcinoma physicochemical property PEOzGAHepG2m evaluated term drug loading efficiency particle size morphology drug release inhibitory effect PEOzGAHepG2m proliferation hepatocellular carcinoma cell assessed CCK8 assay calceinAMPI assay vitro effect unloaded liposome PEOzHepG2m cellular internalization assessed different cell line vivo biodistribution analyzed nearinfrared NIR fluorescence imaging antitumor effect PEOzGAHepG2m vivo evaluated HepG2 tumorbearing nude mice PEOzHepG2m liposome exhibit excellent targeting ability toward HepG2 cells PEOzGAHepG2m possesses high delivery efficiency remarkably therapeutic effect vitro vivo coating HepG2 cell membrane could significantly enhance tumortargeting effect liposome improve antitumor effect loaded drug GA vivo indicating activetargeting biomimetic liposome PEOzGAHepG2m promising nanoplatform delivery drug hepatocellular carcinoma",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819158/",
        "source_type": "Global"
    },
    {
        "pmid": "40819156",
        "title": "Diagnostic accuracy of CT for identifying high-risk colon cancer: a systematic review and meta-analysis.",
        "abstract": "systematic review metaanalysis aimed assess diagnostic accuracy CT differentiating highrisk lowrisk colon cancer focus staging parameter impact CT slice thickness systematic search Ovid MEDLINE Embasecom conducted January 1 2015 September 24 2024 identify study evaluating CTbased staging accuracy using histopathology reference standard QUADAS2 tool assessed risk bias Pooled sensitivity specificity diagnostic odds ratio DOR calculated using bivariate randomeffects model Subgroup analysis explored influence CT techniques slice thickness study design diagnostic performance metaanalysis included fortyfour studies CT demonstrated 83 sensitivity 95 CI 7986 70 specificity 95 CI 6674 detecting pT3T4 tumor DOR 100 pT3cdT4  5 mm muscularis propria invasion sensitivity 67 6173 specificity 88 8392 DOR 137 90210 Detection pN yielded 64 sensitivity 6068 67 specificity 6272 DOR 35 3042 Sensitivity extramural venous invasion EMVI 49 4156 77 specificity 6784 DOR 30 2044 Studies  5 mm slice thickness showed higher sensitivity lower specificity High I² value indicated substantial heterogeneity across studies CT demonstrates high sensitivity detecting T3T4 colon cancer moderate sensitivity nodal involvement EMVI Diagnostic performance varies technical factors emphasizing need standardized imaging protocol supplementary diagnostic tool improve colon cancer staging PROSPERO International Prospective Register Systematic Reviews CRD42022374615 Question Accurate CT staging crucial guiding neoadjuvant therapy colon cancer ability distinguish highrisk lowrisk case remains uncertain Findings CT showed high sensitivity distinguishing pT3T4 tumor moderate sensitivity pT3cdT4 nodal involvement extramural venous invasion Clinical relevance systematic review critically evaluates CT diagnostic accuracy colon cancer staging revealing strength limitations finding highlight need optimized imaging protocol complementary tool enhance risk stratification guide clinical decisions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819156/",
        "source_type": "Global"
    },
    {
        "pmid": "40819152",
        "title": "Education and training of surgical residents in upper gastrointestinal surgery: a European survey.",
        "abstract": "Educating training young surgeon complex challenge requires structured pathway Upper gastrointestinal UGI surgery becoming highly attractive subspecialty yet universally recognized Currently standardized guideline curriculum UGI surgical training across Europe wide disparity among country remains study aim focus current European landscape perspective trainee trainers provide foundation developing effective guideline education training surgical residents conducted crosssectional survey study targeted question various aspect managing patient UGI diseases including preoperative investigations surgical interventions interventional endoscopy postoperative followup also assessed availability training resource extracurricular activities Distinct questionnaire distributed independently trainee trainers overall response rate 356 trainee trainer recognized need dedicated course UGI surgery emphasized importance learning video materials survey revealed surgeon often unfamiliar UGI endoscopy functional esophageal function studies analyzed residents direct involvement three surgical procedures antireflux surgery gastrectomy esophagectomy Residents expressed lack confidence executing certain surgical steps trainer resident expressed preference extracurricular handson course focused UGI surgery reported insufficient opportunity training survey highlight significant gap limitation UGI training surgical resident Europe Efforts toward standardization development specific guideline recommendation required enhance education UGI surgery",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819152/",
        "source_type": "Global"
    },
    {
        "pmid": "40819151",
        "title": "An interpretable CT-based deep learning model for predicting overall survival in patients with bladder cancer: a multicenter study.",
        "abstract": "Predicting prognosis bladder cancer remains challenging despite standard treatments developed interpretable bladder cancer deep learning BCDL model using preoperative CT scan predict overall survival model trained cohort n  765 validated three independent cohort n  438 n  181 n  72 BCDL model outperformed model survival risk prediction SHapley Additive exPlanation method identifying pixellevel feature contributing predictions Patients stratified high lowrisk group using deep learning score cutoff Adjuvant therapy significantly improved overall survival highrisk patient p  0028 woman lowrisk group p  0046 RNA sequencing analysis revealed differential gene expression pathway enrichment risk groups highrisk patient exhibiting immunosuppressive microenvironment altered microbial composition BCDL model accurately predicts survival risk support personalized treatment strategy improved clinical decisionmaking",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819151/",
        "source_type": "Global"
    },
    {
        "pmid": "40819148",
        "title": "Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.",
        "abstract": "operative standard melanoma implemented Commission Cancer CoC address margin width excision depth collect information sentinel lymph node biopsy SLNB However SLNB implemented technical standard breast cancer also critical management melanoma impact nodal staging study aimed characterize current facilitylevel variation nodal yield nodal positivity determine opportunity improvement standardization Using National Cancer Database identified patient T1bT4 melanoma trunk upper extremity underwent SLNB 2018 2022 Reliabilityadjusted estimate nodal yield nodal positivity calculated using Poisson regression logistic regression random intercept hospitals identified 48653 melanoma patient 1167 facilities SLNB median nodal yield 24 IQR 2227 ranging 14 70 SLNB median nodal positivity 180 IQR 171195 ranging 116 405 weak correlation nodal yield nodal positivity observed Spearman correlation coefficient  008 p  0009 Facilitylevel variation nodal yield minimal weakly correlated nodal positivity suggests SLNB performed melanoma trunk upper extremity well standardized across CoC hospital absence defined operative standard Future effort improve quality melanoma nodal surgery may best focused technical element procedures lymphadenectomy novel lymph node dissection approach following neoadjuvant therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819148/",
        "source_type": "Global"
    },
    {
        "pmid": "40819143",
        "title": "Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma.",
        "abstract": "Glioblastoma aggressive treatmentrefractory primary brain tumor limited therapeutic option high recurrence molecular heterogeneity glioblastoma pose significant challenge therapeutic development targeted therapy mostly failed smallscale clinical trials underscoring need comprehensive nextgeneration sequencing NGS characterization identify mechanism resistance study identify functionally characterize novel amplified fusion MDM2 exon 1PDGFRA exon 8 mediating resistance cetuximab EGFRamplified glioblastoma fusion result truncated PDGFRA isoform vitro assay demonstrate MDM2PDGFRA act constitutively active oncogenic driver distinct sensitivity profile tyrosine kinase inhibitors Analysis glioblastoma cohort indicates PDGFRA structural variant often cooccur amplification may serve biomarkers finding highlight importance repeat NGS profiling clinical management provide translational framework identifying targeting emergent fusiondriven alterations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819143/",
        "source_type": "Global"
    },
    {
        "pmid": "40819134",
        "title": "Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors.",
        "abstract": "Designing efficient biocompatible radiationsensitive material activate systemic immune response maximize tumoricidal effect malignant tumors Here inspired natural Mnperoxidase propose de novo design RuMnoxygen complex MnBTCRu biocatalytic radiosensitization therapy eradicate primary metastatic tumors result reveal Mnorganic ligand enhance electron density Ru clusters thereby optimizing binding oxygen specie resulting high reactive oxygen specie oxygen generation Accordingly MnBTCRu radiation enhance cell membrane DNA damage triggering apoptosis though oxidative damage heightening radiosensitization activating CD8supsup cells combined antiPD1 therapy synergistic approach generates robust systemic antitumor response female mice promoting abscopal effect establishing enduring immune memory tumors thereby reducing recurrence metastasis design present superior biocatalytic radiosensitizing properties may provide promising practical bionanotechnology future treatment eradicating primary metastatic tumors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819134/",
        "source_type": "Global"
    },
    {
        "pmid": "40819132",
        "title": "Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates.",
        "abstract": "Epithelial ovarian cancer largely comprised immunogenic tumor subtypes degree CD8 cell infiltration prognostic clinical outcome Tumor antigenspecific cell identified among infiltrating cell population spurred decade development towards antigenspecific immunotherapies Despite efforts success immunotherapy shown limited study used stateofthe art immunopeptidomics approach novel proteogenomic profiling method identify potential immunogenic human leukocyte antigen class Ipresented peptide patientderived highgrade serous ovarian cancer 11 patients tumors identified promising candidate therapeutic potential these selected best 13 candidate validated immunogenicity healthy donor cancer patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819132/",
        "source_type": "Global"
    },
    {
        "pmid": "40819114",
        "title": "LncSNHGs: new targets in osteosarcoma.",
        "abstract": "Long noncoding RNAs lncRNAs attracted significant attention role tumor initiation progression Specifically studying lncRNA small nucleolar RNA host gene lncSNHGs opened new possibility treatment osteosarcoma OS review aim give thorough overview state research biological roles molecular mechanisms expression lncRNA SNHG family OS extensive analysis demonstrated member SNHG family exhibit dysregulated expression pattern OS dysregulations affect multiple oncogenic processes including tumor proliferation metastasis apoptosis autophagy chemotherapy resistance lncRNA SNHG family promise identify novel strategy target diagnosing treating prognosis OS",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819114/",
        "source_type": "Global"
    },
    {
        "pmid": "40819112",
        "title": "Integrated spatial transcriptome and metabolism study reveals metabolic heterogeneity in human bladder cancer.",
        "abstract": "Bladder cancer BC malignancy originates cell lining bladder one common cancer urinary system capable occurring part bladder However molecular mechanism underlying malignant transformation BC systematically studied study integrated cuttingedge technique spatial transcriptomics ST spatial metabolomics SM capture transcriptomic metabolomic landscape BC adjacent normal tissues ST result revealed significant upregulation gene associated choline metabolism glucose metabolism gene related sphingolipid metabolism tryptophan metabolism significantly downregulated Additionally significant metabolic reprogramming observed BC tissues including upregulation choline metabolism glucose metabolism well downregulation sphingolipid metabolism tryptophan metabolism alteration may play crucial role promoting tumorigenesis immune evasion BC interpretation ST SM data study offer new insight molecular mechanism underlying BC progression provides valuable clue prevention treatment BC Schematic illustration BC metabolic reprogramming",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819112/",
        "source_type": "Global"
    },
    {
        "pmid": "40819076",
        "title": "Programmed death 1 inhibitor combined with radiotherapy decreases epidermal growth factor receptor expression in breast cancer.",
        "abstract": "investigate effect programmed death 1 PD1 inhibitor combined radiotherapy expression P53 epidermal growth factor receptor EGFR breast cancer BC impact radiation treatment BC patients prognosis examined data BC patient admitted Nanjing University Chinese Medicine April 2022 April 2023 retrospectively analyzed clinical data patient extracted 104 patient randomly enrolled survival time complication patient followed up expression level P53 EGFR tumor tissue prognosis patient treated PD1 inhibitor combined radiotherapy analyzed expression level EGFR joint group JG visibly lower control group CG median progressionfree survival PFS JG visibly longer CG all P  005 optimal cutoff value P53 positive rate EGFR level combined treatment 10 9621ngmL addition median PFS individual low EGFR JG 73 visibly higher individual high EGFR level EGFR PD1 inhibitor treatment independent cause risk affecting prognosis patients PD1 inhibitor plus radiotherapy effectively inhibit expression EGFR tumor tissue BC patient visibly improve prognosis applicable",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819076/",
        "source_type": "Global"
    },
    {
        "pmid": "40819062",
        "title": "Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis.",
        "abstract": "Cyclindependent kinase 46 inhibitor CDK46i plus endocrine therapy ET mainstay treatment hormone receptor positive HER2 negative HR  HER2 metastatic breast cancer MBC However disease progression inevitable unveiling resistance mechanism crucial guide postCDK46i therapeutic strategies study retrospectively analyzed realworld multiinstitutional cohort patient HR  HER2 MBC characterized circulating tumor DNA ctDNA nextgeneration sequencing NGS starting secondline treatment Among 93 patient previously treated CDK46i PIK3CA 376 ESR1 462 TP53 312 altered genes Comparing CDK46i plus ET naïve control cohort ESR1 p  0001 significantly associated firstline exposure multivariable analyses PTEN alteration independently associated shorter progression free survival PFS p  0008 overall survival OS p  0006 TP53 p  0031 CCDN1 p  0003 ET secondline clinicians choice p  0011 impacted OS Moreover lowmutant allele frequency correlated longer PFS p  0017 OS p  0038 finding highlight prognostic relevance specific molecular alteration support role genomic profiling guiding secondline treatment decision CDK46i therapy Prospective validation warranted confirm clinical utility approach HR  HER2  MBC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819062/",
        "source_type": "Global"
    },
    {
        "pmid": "40819058",
        "title": "Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer.",
        "abstract": "Triplenegative breast cancer TNBC highly aggressive breast cancer subtype associated highest mortality rate among breast cancer subtypes primarily due absence actionable therapeutic targets Although poly ADPribose polymerase inhibitor PARPi shown promising therapeutic effect TNBC patient harboring homologous recombination deficiency HRD clinical benefit remains limited highlighting urgent need novel target enhance PARPi efficacy study investigates role Jab1 regulating stability homologous recombination repair HRRrelated RNAs evaluates potential therapeutic target enhance PARPi sensitivity TNBC RNASeq analysis revealed shRNAmediated Jab1 knockdown profoundly affected HRR DNA replication process TNBC cells Using Nuclear RunOn Assay RNA Immunoprecipitation RNA PullDown Assay RIPSeq identified Jab1 potential RNAbinding protein RBP stabilizes HRRrelated mRNAs competing exosome complex Genetic pharmacological inhibition Jab1 using CSN5i3 evaluated impact HRR efficiency ionizing radiation IR sensitivity PARPi sensitivity comprehensive panel vitro assay performed including clonogenic survival assays PrestoBlue assays apoptosis assays DRGFP reporter assays qRTPCR Western blot comet assays immunofluorescence vivo efficacy assessed using zebrafish xenografts nude mouse xenografts syngeneic orthotopic mouse model examine therapeutic effect Jab1 inhibition combination PARPi Jab1 found overexpressed TNBC correlated poor clinical outcomes Functional analysis revealed Jab1 knockdown impaired HRR increased DNA damage accumulation sensitized TNBC cell IR PARPi irrespective BRCA mutation status Mechanistically Jab1 functioned RBP MPN domain stabilizing HRRrelated transcript competitively antagonizing RNA exosome complex Pharmacological inhibition Jab1 using CSN5i3 recapitulated effect synergized PARPi induce synthetic lethality multiple preclinical models combination significantly suppressed tumor growth promoted apoptosis study uncovers novel role Jab1 RBP specifically interaction MPN domain HRRrelated RNAs regulating RNA stability maintaining HRR competency Targeting Jab1 represents promising strategy pharmacologically induce HRD enhance efficacy PARPi therapy TNBC combination approach may hold translational value improving clinical outcome patient TNBC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819058/",
        "source_type": "Global"
    },
    {
        "pmid": "40819038",
        "title": "Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma.",
        "abstract": "optimal treatment strategy patient borderline resectable cT3br esophageal squamous cell carcinoma ESCC remains unclear Thus aim study compare perioperative outcome prognosis neoadjuvant chemotherapy combined immunotherapy NACI neoadjuvant chemoradiotherapy NCRT cT3br ESCC patients retrospective cohort study patient cT3br ESCC received either NACI NCRT followed surgery January 2016 December 2022 identified Propensity score matching PSM used minimize influence confounding factors Survival curve constructed analyzed using KaplanMeier logrank survival analysis 97 patient cT3br ESCC received NACI 111 received NCRT PSM R0 resection rate 857 vs 905 P  0341 pCR rate 190 vs 262 P  0269 comparable two groups MPR rate NACI group significantly lower NCRT group 321 vs 560 P  0002 However NCRT associated greater risk severe postoperative complication 214 vs 60 P  0004 3year overall survival 694 vs 557 P  0242 diseasefree survival 557 vs 497 P  0242 overall recurrence 321 vs 298 P  0739 recurrence pattern comparable NACI NCRT groups NACI followed surgery appears safe effective treatment strategy patient borderline resectable ESCC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819038/",
        "source_type": "Global"
    },
    {
        "pmid": "40819037",
        "title": "Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.",
        "abstract": "study aimed compare efficacy neoadjuvant chemoradiotherapy NCRT chemotherapy NCT chemoimmunotherapy NCIT patient locally advanced esophageal squamous cell carcinoma LAESCC primary objective assess overall survival OS among three treatment groups retrospective cohort 625 patient treated Fourth Hospital Hebei Medical University 2016 2022 analyzed Patients received NCRT NCT NCIT followed radical esophagectomy adjust confounding factors inverse probability treatment weighting IPTW employed Chisquare tests Fishers exact tests multivariate Cox survival analysis used assess prognostic factor survival outcomes IPTW significant difference baseline characteristic observed among three groups IPTW adjustment difference mitigated allowing balanced comparison NCIT demonstrated superior 4year OS rate 914 compared NCRT 604 NCT 625 addition adjuvant therapy improved survival outcomes NCIT may offer superior survival benefit NCRT NCT patient LAESCC particularly combined adjuvant chemoimmunotherapy ACIT finding underscore potential immunotherapy multimodal treatment LAESCC warrant investigation prospective clinical trials",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819037/",
        "source_type": "Global"
    },
    {
        "pmid": "40819029",
        "title": "Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial.",
        "abstract": "efficacy safety conventional firstline chemotherapeutic regimen treatment advanced biliary tract carcinoma ABTCs unsatisfactory aimed explore alternative chemotherapeutic regimen capable providing improved efficacy fewer sideeffects Multicentre randomised phase II clinical trial Patients unresectable advancedstage tumors developed recurrence metastasis following initial radical surgery January 2021 November 2022 included participant randomised either gemcitabinecisplatin group GC albuminpaclitaxelcisplatin group NC Progressionfree survival PFS primary outcome whereas overall survival OS objective response rate ORR secondary outcomes trial enrolled 75 patient median followup period 11 months median PFS mPFS 78 95 confidence interval CI 54140 m NC group 70 95CI 39101 m GC group p  00034 hazard ratio HR  05136 95CI 0313608411 Median OS NC group 124 95CI 73223 m GC group 121 95CI 67207 m significant difference p  04592 HR  0811 95CI 04631442 PFS rate 6 8 month 526 vs 730 132 vs 351 NC GC group respectively p  005 secondary endpoint ORR rates significant difference two groups GC group 13 342 patient achieved ORR NC group 14 378 Regarding safety context thrombocytopenia incidence significantly lower NC group compared GC group 27 v 50 P  0041 Conversely regard sensory neuropathy NC group demonstrated higher incidence 621 v 368 P  0028 phase II noninferiority trial NC demonstrated comparable efficacy GC advanced BTC trend toward improved PFS potentially favorable hematological toxicity profile study warranted confirm finding context modern immunotherapybased standard Clinical Trialsgov identifiers NCT04692051 Registered October 31 2018 httpswwwchictrorgcnshowprojhtmlproj38440 ",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819029/",
        "source_type": "Global"
    },
    {
        "pmid": "40819022",
        "title": "Diagnosis and treatment outcomes of primary lymphoma of the thyroid gland.",
        "abstract": "Primary thyroid lymphoma PTL rare extranodal malignancy accounting less 5 thyroid cancer unique algorithm management contrast type thyroid cancer surgery cornerstone management PTL usually show female predominance diffuse large Bcell lymphoma DLBCL prevalent pathological subtype study aimed assess thyroid lymphomas epidemiology pattern relapse diagnostic approaches prognostic features presenting 165year experience tertiary referral oncology center retrospective study assessed PTL patient managed January 2008 June 2024 tertiary referral center clinical diagnostic therapeutic followup data analyzed Sixteen patient included mean age 5934 year femaletomale ratio 17 case 688 diagnosed stage II DLBCL identified 938 patients Remission achieved half patient firstline therapy cure following secondline treatments patient died stage II time diagnosis median diseasefree survival DFS 35 months overall survival OS 375 months aware PTL facilitate timely initiation treatment Chemotherapy definitive treatment used alone surgery done diagnostic purposes PTL good prognosis however latestage disease linked worse outcomes study underscore importance multimodal diagnostic therapeutic strategy highlighting need research rare malignancy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819022/",
        "source_type": "Global"
    },
    {
        "pmid": "40819002",
        "title": "Integrative machine learning models predict prostate cancer diagnosis and biochemical recurrence risk: Advancing precision oncology.",
        "abstract": "Prostate cancer PCa rank among prevalent cancer men worldwide Biochemical recurrence BCR present major clinical challenge PCa management significant prognostic heterogeneity observed among patient postrecurrence study aimed develop machine learning model predicting diagnosis prognosis PCa patients Using WGCNA initially identified 16 BCRrelated target genes Cluster analysis revealed gene significantly associated PCa prognosis drug sensitivity immune infiltration constructed robust diagnostic model integrating multiple machine learning algorithms demonstrating strong predictive capability PCa Furthermore BCRrelated prognostic model built using LASSO algorithm also yielded satisfactory performance Among differentially expressed BCRassociated prognostic genes COMP emerged critical regulatory factor vitro vivo experiment confirmed COMPs role influencing PCa progression Additionally COMP demonstrates significant potential dual biomarker diagnosis recurrence prediction PCa",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819002/",
        "source_type": "Global"
    },
    {
        "pmid": "40818987",
        "title": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.",
        "abstract": "Management paradigm newlydiagnosed acute myeloid leukemia NDAML patient considered unfit receive intensive chemotherapy evolved improved understanding disease biology setting management requires clear delineation goal therapy include preservation qualityoflife QoL Combination venetoclax Ven hypomethylating agent HMA current standardofcare circumstance flexible option regard drug dose duration treatment well addition triplet combinations alternative use targeted therapies inhibitor FLT3 IDH1 IDH2 menin patient NPM1supMUTsup KMT2A rearrangement KMT2Ar Response rate CRCRi4090 overall survival outcome 3year 067 following VenHMA therapy highly variable depend primarily tumor genetics achievement complete response CR without count recovery CRi consolidation allogeneic stem cell transplant ASCT essential securing longterm survival Favorable genomic predictor response VenHMA include NPM1supMUTsup IDH2supMUTsup DDX41supMUTsup unfavorable TP53supMUTsup FLT3ITD KNRASsupMUTsup Favorable predictor overall survival include IDH2supMUTsup unfavorable TP53supMUTsup FLT3ITD KNRASsupMUTsup KMT2Ar Whether triplet regimen provide significant survival gain VenHMA genetically targetable subgroup remains determined Particularly frail patient considered unfit VenHMA might benefit monotherapy targeting FLT3supMUTsup IDH12supMUTsup NPM1supMUTsupor KMT2Ar Future research project focus incorporating patientreported outcome clinical trials optimization VenHMA dosing treatment duration especially triplet combination broadening use ASCT clarification timing",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818987/",
        "source_type": "Global"
    },
    {
        "pmid": "40818979",
        "title": "Global, regional, and national burden trends of lip and oral cavity cancer among individuals aged 60 and above from 1990 to 2021: a systematic analysis based on the 2021 global burden of disease data.",
        "abstract": "Lip oral cavity cancer LOCC one common malignancy among elderly facing challenge insufficient early diagnosis difficulty latestage treatment propensity metastasis recurrence contribute poor prognoses However remains lack systematic analysis regarding global regional national burden LOCC specifically within elderly population study utilized data Global Burden Disease GBD 2021 database including agestandardized incidence rate ASIR agestandardized prevalence rate ASPR agestandardized mortality rate ASMR agestandardized disabilityadjusted life year ASDR comprehensive analysis conducted burden LOCC among elderly across globe five social development index SDI regions 21 GBD regions 204 countries examining current status trends future projections attributable risk factors 1990 2021 burden LOCC among elderly significantly increased although growth trend slowed recent years 2021 ASIR LOCC 2313 per 100000 ASPR 7219 per 100000 ASMR 1257 per 100000 ASDR 25310 per 100000 years increasing SDI ASIR ASPR continued rise ASMR ASDR exhibited gradual decline absolute relative health inequality different country gradually diminished burden disease increased age male females male experiencing higher burden females Projections indicate 2022 2050 ASR LOCC continue rise Major risk factor identified LOCC include chewing tobacco high alcohol consumption smoking Since 1990 burden LOCC among elderly consistently increased trend expected continue future despite slowdown rate increase recent years Furthermore burden disease exhibit degree inequality based age gender region",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818979/",
        "source_type": "Global"
    },
    {
        "pmid": "40818975",
        "title": "Computational ranking identifies Plexin-B2 in circulating tumor cell clustering with monocytes in breast cancer metastasis.",
        "abstract": "Multicellular circulating tumor cell CTC cluster 50 time efficient single CTCs mediating viable metastasis Here combining computational ranking functional determination identify transmembrane protein PlexinB2 PLXNB2 one top molecular target associated unfavorable distant metastasisfree survival showing enriched expression CTC cluster versus single CTCs patient advanced breast cancer mostly female Loss PLXNB2 Plxnb2 reduces formation homotypic tumor cell cluster heterotypic tumormyeloid cell clusters reducing spontaneous metastasis female mouse bearing human mouse breast cancer Interactions PLXNB2 ligand SEMA4C tumor cell SEMA4A myeloid cell monocytes promote homotypic heterotypic CTC cluster formation respectively thereby driving lung metastasis Global proteomic analysis reveals downstream effector PLXNB2 pathway associated tumor cell clustering Thus PLXNB2 therapeutic target preventing new metastasis breast cancer",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818975/",
        "source_type": "Global"
    },
    {
        "pmid": "40818959",
        "title": "Regulatory T cell therapy promotes TGF-β and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2.",
        "abstract": "CD4supsupFoxp3supsup regulatory cell essential maintaining immune tolerance preventing excessive inflammation making promising candidate treating autoimmunity GvHD However translation regulatory cell therapy clinical practice pose substantial challenges Here show adoptive regulatory cell therapy increase IL6 TGFβdependent pathogenic Th17 cell differentiation murine model inflammatory bowel disease experimental autoimmune encephalomyelitis Regulatory cell increase pstat3pstat5 ratio effector cell suppressing IL2 secretion competitively consuming IL2 thereby promoting Th17 cell differentiation Notably IL2 signaling deficiency promotes Th17 cellassociated transcriptional program also enhances proinflammatory property Th17 cells Strikingly therapeutic blockade IL6STAT3 signaling pathway reverse pathogenic Th17 cell differentiation enhance therapeutic effect regulatory cell therapy Thus finding could potentially advance clinical research progress adoptive regulatory cell therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818959/",
        "source_type": "Global"
    },
    {
        "pmid": "40818935",
        "title": "Exploring the gut microbiota associated with peripheral nerve invasion in colorectal cancer patients and constructing predictive models.",
        "abstract": "study aim explore difference composition abundance biological function gut microbiota colorectal cancer CRC patient peripheral nerve invasion PNI without peripheral nerve invasion NPNI Additionally tried construct machinelearning predictive model incorporating identified microbiota characteristic explore impact gut microbiota CRCPNI progression search new noninvasive microbiological indicator CRCPNI Finally successfully developed predictive model predict PNI CRC patient leveraging microbial biomarkers innovative approach expected offer novel strategy early detection CRC metastasis thereby facilitating informed decision regarding treatment options study included 132 colorectal cancer CRC patients divided two separate group according whether exhibited PNI gut microbiota participant subjected 16S rRNA gene sequencing followed thorough analysis identify significant difference groups applied cell sorting algorithm convert transcriptome sequencing data obtained 8 colorectal cancer patient matrix representing immune cell abundance Following this matrix utilized investigate association among PNIrelated distinct gut microbiota immune cells immunerelated genes PNIrelated differentially expressed gene or molecular markers pathways well association KEGG pathways Based differential gut microbiota constructed Random Forest RF Multilayer Perceptron MLP model predict PNI CRC patients Comparative analysis αdiversity βdiversity gut microbiota CRC patient without PNI revealed statistically significant difference P  005 However Linear Discriminant Analysis effect size LEfSe identified 35 distinct gut microbiota 28 specie enriched PNI group 7 specie significantly enriched NPNI group analyzing gut microbiota significantly associated PNI successfully constructed predictive model using RF MLP predict occurrence PNI CRC patients model demonstrated robust performance PNI NPNI groups 35 gut microbiota specie exhibited significant variation abundance differential intestinal microbiota associated PNI colorectal cancer may modulate neuroinvasion process via variety potential biological mechanisms RF MLP predictive model show considerable accuracy predicting CRCPNI status reference value",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818935/",
        "source_type": "Global"
    },
    {
        "pmid": "40818843",
        "title": "Efruxifermin: one step closer to disease-modifying therapy in fibrotic MASH.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818843/",
        "source_type": "Global"
    },
    {
        "pmid": "40818831",
        "title": "Current Insights on Transglutaminase 2: Exploring Its Functions, Mechanisms, and Therapeutic Potential in Glioblastoma.",
        "abstract": "Glioblastoma GBM aggressive lethal primary brain tumor adults marked diffuse infiltration extensive heterogeneity resistance standard therapies Despite advance surgery radiation chemotherapy GBM remains incurable median survival 15 months Tumor recurrence driven therapyresistant glioma stem cell adaptive molecular mechanisms present significant challenge treatment Identifying regulator GBM progression resistance crucial developing effective interventions Transglutaminase 2 TGM2 ubiquitously expressed enzyme Casup2supdependent independent activities emerged pivotal yet underexplored contextspecific contributor various malignancies Aberrant TGM2 expression linked hallmark feature GBM including stemness invasion epithelialtomesenchymal transition chemoradioresistance However multifunctionality conformational flexibility widespread subcellular localization complicated effort delineate precise oncogenic mechanisms Conflicting data suggest TGM2 may promote survival apoptosis underscoring need nuanced investigation review provides overview TGM2s structural features biochemical functions regulatory mechanisms focus role GBM progression resistance chemoradiotherapy Emerging evidence implicates TGM2 enhancing DNA repair promoting cellular plasticity evading apoptosis contribute tumor survival Targeting TGM2 shown promise preclinical studies especially inhibitor exhibit potential cross bloodbrain barrier addressing major challenge effective GBM therapy integrating molecular translational insights review highlight TGM2 promising therapeutic target overcoming resistance advancing combined precision strategy GBM treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818831/",
        "source_type": "Global"
    },
    {
        "pmid": "40818830",
        "title": "Role of Bcl-2 Family Anti-apoptosis Inhibition in Overcoming Therapeutic Resistance in Prostate Cancer: A Systematic Review.",
        "abstract": "Therapeutic resistance continues pose one major problem effectively managing prostate cancer PCa advancement therapeutic resistance key mechanism underlying resistance suppression apoptosis often triggered increased expression antiapoptotic Bcl2 family proteins evaluate outcome combining standard prostate cancer therapy inhibitor targeting Bcl2 family antiapoptotic proteins systematic literature research screened using PubMed database Scopus EBSCOhost Medline Ultimate database October 30 2024 Studies investigating combination standard PCa therapy Bcl2 family antiapoptosis inhibitor included Study assessment analysing data quality assessment independently conducted four reviewers Twelve study fulfilled inclusion criteria Six employed vitro methods remaining six used vitro vivo approaches standard therapy evaluated included androgen deprivation castration antiandrogens chemotherapy study utilized nonselective Bcl2 family inhibitors including ABT263 ABT737 well selective Bcl2 inhibitor ABT199 However study employed selective inhibitor BclxL Mcl1 selected study indicated antiapoptotic inhibitor amplified cytotoxic efficacy conventional treatment also demonstrated senolytic properties effectively mitigating therapyinduced cellular senescence systematic review demonstrates inhibition Bcl2 family antiapoptotic protein potentiate efficacy standard treatment prostate cancer finding provide compelling rationale research targeted combination therapy overcome therapeutic resistance PCa",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818830/",
        "source_type": "Global"
    },
    {
        "pmid": "40818829",
        "title": "35 Years of Palliative Care Progress: What Lies Ahead for Society Engagement?",
        "abstract": "modern palliative care began 50 year ago formal recognition 1990 marked turning point Since then palliative care evolved niche service terminal cancer patient global health priority integrated universal health coverage Despite notable progress serious suffering related health condition continues rise especially low middleincome countries calling renewed ethical strategic commitment critically review historical trajectory palliative care development compare global frameworks highlight regional disparities propose forwardlooking strategy evaluation implementation special article present narrative synthesis key policy milestones conceptual transitions global indicator development palliative care contrast two WHOendorsed public health models 2007 Umbrella strategy 2021 House framework analysing complementarity global relevance Major shift include broader definition palliative care increased governmental engagement expanded outcome measures stronger emphasis equity community involvement Despite advances access remains deeply unequal across within world regions Recent initiatives indicator framework global commissions provide renewed tool ethical imperative progress future global palliative care depends political will fair allocation resources robust monitoring meaningful community participation renewed public health approach grounded compassion human rights local empowerment essential address projected increase healthrelated suffering 2060 ensure one left behind article support clinicians policymakers researcher aligning practice emerging global standards ethical mandates communitybased innovation ensure one left behind",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818829/",
        "source_type": "Global"
    },
    {
        "pmid": "40818826",
        "title": "Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry.",
        "abstract": "Cord blood CB transplantation fallen disfavor association low cell dose high nonrelapse mortality NRM However phase III trial using UM171expanded CB transplantation patient highrisk hematologic malignancy lacked suitable donor demonstrated promising results including prompt neutrophil engraftment ability use smaller better human leucocyte antigen HLA matched CB units low NRM rate 5 retrospective matched paired analysis conducted test hypothesis UM171expanded CB transplantation provides outcome equivalent superior conventional hematopoietic stem cell donor sources primary objective neutrophil engraftment NRM graft versus host disease GVHDfree relapsefree survival GRFS retrospective study compared outcome 22 adult patient received single UM171expanded CB transplant phase III trial six cohort patient allografted different stem cell sources reported European Society Blood Marrow Transplantation EBMT registry six donor control cohort included 1 unmanipulated CB 2 peripheral blood stem cell PBSC 1010 HLAmatched unrelated donor 1010 MUD 3 bone marrow BM 1010 MUD 4 910 matched unrelated donor 910 UD 5 cell replete haploidentical haplo donor 6 HLA matched sibling donor MSD Direct propensity score matching used patient disease transplant characteristic ensure comparability analyzed endpoint included engraftment GVHD NRM relapse progressionfree survival PFS overall survival OS GRFS Neutrophil engraftment generally similar donor group slower unmanipulated CB MUD BM moderate severe chronic GVHD UM171 CB recipients significantly lower rate compared PBSC MUD BM MUD MSD transplants PFS OS GRFS significantly better UM171 CB seen haplo donor transplants GRFS also consistently superior UM171 CB compared 1010 MUD PBSC 910 UD MSD transplants UM171expanded CB recipient equivalent improved short longterm outcome compared patient transplanted graft sources",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818826/",
        "source_type": "Global"
    },
    {
        "pmid": "40818805",
        "title": "Growth Patterns in Shwachman-Diamond Syndrome: Findings from the North American Shwachman-Diamond Syndrome Registry.",
        "abstract": "characterize growth pattern individual ShwachmanDiamond Syndrome SDS North America generating SDSspecific growth curve assessing impact hematopoietic stem cell transplant HSCT growth hormone GH growth conducted retrospective cohort study 127 subject confirmed biallelic SBDS mutation enrolled North American SDS Registry Height weight BMIforage Zscores analyzed compared Centers Disease Control Prevention CDC World Health Organization reference populations effect HSCT GH therapy growth velocity final height outcome assessed Individuals SDS demonstrated significantly lower heightforage Zscores HAZ median adult height approximately 7 cm shorter female 11 cm shorter male compared CDC standards Although weightforage diminished BMIforage trajectory preserved HSCT significantly reduced HAZ slope small subsample GH therapy showed limited efficacy improving final height study SDS across diverse North American sample extends available growth data rare condition confirming persistent short stature normal BMI age SDS HSCT associated reduction growth significant change height velocity observed GH therapy data inform clinical growth evaluation SDS patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818805/",
        "source_type": "Global"
    },
    {
        "pmid": "40818720",
        "title": "A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle.",
        "abstract": "Ionizable cationic lipid critical construction lipid nanoparticles LNPs mRNA delivery Here reported rational design evaluation FS01 novel ionizable cationic lipid incorporating orthobutylphenylmodified hydrophobic tail squaramidebased lipid headgroup architecture Molecular dynamic simulation revealed FS01 enhances mRNA stability ππ stacking interaction aromatic tail nucleobases aromatic rings alongside hydrogen bonding via squaramide headgroup FS01LNPs demonstrated smaller particle size  70 nm high encapsulation efficiency  90  superior mRNA delivery performance across intramuscular subcutaneous intravenous route mouse compared FDAapproved lipid DlinMC3DMA SM102 ALC0315 prophylactic vaccine model Varicellazoster virus Hepatitis B virus FS01LNP formulation elicited robust antigenspecific antibodies memory B cells Th1biased cell responses outperforming benchmark LNPs Further transcriptomic profiling safety assessment demonstrated FS01LNP induced wellbalanced innate immune activation minimal inflammation liver toxicity contrasting pronounced reactogenicity DlinMC3DMA ALC0315 LNPs finding highlighted FS01 promising ionizable lipid candidate mRNA therapeutics offering enhanced delivery efficiency immunogenicity safety potential application extending beyond vaccine gene editing protein replacement therapies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818720/",
        "source_type": "Global"
    },
    {
        "pmid": "40818717",
        "title": "Stimulator of interferon genes-targeted positron emission tomography tracks early microbiota-induced tumor immune remodeling and guides immunotherapy.",
        "abstract": "Immune checkpoint inhibitor ICIs made dramatic evolution cancer management yet curative effect remains limited tumor characterized cold immunophenotype Immune remodeling transforming cold tumor hot one essential improve ICIs response gut microbiota modulation emerged promising approach Nevertheless significant challenge lie absence reliable tool early assessment immune remodeling address this focused stimulator interferon gene STING essential molecule launching antitumor immunity developed STINGtargeted PET tracer sup18supFFBTA sup18supFFBTAPET detected significant increase tumor uptake homogeneous spatial distribution following Lactobacillus rhamnosus GG LGG treatment increased sup18supFFBTA uptake prior change tumor volume cell infiltration sup18supFFDGPET signals showed strong correlation STING expression tumor tissues immune remodeling mediated LGG administration captured sup18supFFBTAPET also successfully replicated recipient mouse fecal microbiota transplantation Guided sup18supFFBTAPET combination LGG αPDL1 achieved superior antitumor efficacy Furthermore sup18supFFBTA binding radioactivity positively correlated STING expression patients tumor tissues result established sup18supFFBTAPET robust indicator early assessment immune remodeling guiding ICIbased combination therapies highlighting potential clinical translation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818717/",
        "source_type": "Global"
    },
    {
        "pmid": "40818708",
        "title": "TRANSFORMING HEALTHCARE: THE FRONTIER OF INTEGRATIVE MEDICINE.",
        "abstract": "Inflammatory bowel disease IBD chronic condition significant clinical socioeconomic burdens Multidisciplinary IBD Team emerged gold standard IBD management offering holistic patientcentred approach integrates clinicians surgeon allied professional complimentary skill sets review examines international evidence supporting multidisciplinary implementation highlighting improved clinical economic logistical outcomes 59 study identified systematic search Medline OVID Studies involving member multidisciplinary team isolation whole team variation included analysis Despite strong endorsement national standards access multidisciplinary care remains uneven minority service providing full integration Barriers include funding workforce shortages geographic inequities current data support multidisciplinary efficacy standardized research needed particularly lowresource rural settings rising IBD prevalence widespread adoption multidisciplinary model essential sustainable highquality care delivery",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818708/",
        "source_type": "Global"
    },
    {
        "pmid": "40818628",
        "title": "Evolving Risk Factors and Predisposing Conditions of Pneumocystis Pneumonia in Non-HIV Patients: A Seven-Year Multicenter Study.",
        "abstract": "Pneumocystis pneumonia PCP increasingly develops nonHIV patient without established immunocompromising factors study examined evolving predisposing factor atrisk medications multicenter retrospective study included nonHIV PCP seven clinical center 20162023 Patients categorized exposed medication underlying predisposing diseases Demographic characteristics disease severity treatment approaches outcome reported 470 nonHIV PCP identified 420 probable case included analysis proportion PCP without established highrisk medication increased 47 2016 61 2023 209 498 received established highrisk medications 106 252 suspected atrisk medications 155 369 atrisk medications Subjects established highrisk medication likely hematological malignancy 502 P0001 suspected atrisk medication higher rate solid cancer 632 P0001 transplantation 245 P0001 Overall mortality rate 438 60day comparable mortality across medication group logrank P008 significant difference disease category logrank P0001 solid cancer exhibited worst outcome 580 epidemiology nonHIV PCP evolving beyond traditional risk categories emerging highrisk medication predisposing comorbidities might require investigation addressed prophylaxis guidelines",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818628/",
        "source_type": "Global"
    },
    {
        "pmid": "40818609",
        "title": "The chromatin remodeling factor BAP18 promotes non-small cell lung cancer progression via the recruitment of β-Catenin with the transcriptional coactivator complex ACTL6A-PAF1.",
        "abstract": "Nonsmall cell lung cancer NSCLC prevalent deadly form lung cancer treatment challenge including drug resistance limited therapeutic targets despite advance immune checkpoint inhibitor ICIs study investigated role BAP18 chromatinassociated protein NSCLC progression potential therapeutic target NSCLC tissue sample analyzed BAP18 expression using Western blot immunohistochemistry NSCLC cell line BAP18 knockdown assessed proliferation migration cell cycle tumor growth vitro assay xenograft models Coimmunoprecipitation luciferase reporter assay used explore BAP18s interaction βcatenin ACTL6A PAF1 impact βcateninmediated transcriptional activity RNA sequencing enrichment analysis identified pathway involved BAP18regulated NSCLC progression result showed BAP18 highly expressed NSCLC tissues knockdown significantly inhibited cell proliferation migration tumor growth Mechanistically BAP18 recruit ACTL6A PAF1 Wnt target gene promoters enhancing βcateninmediated transcription finding suggest BAP18 play critical role NSCLC progression Wntβcatenin pathway could serve novel therapeutic target particularly patient Wntβcatenindriven tumors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818609/",
        "source_type": "Global"
    },
    {
        "pmid": "40818587",
        "title": "Single-cell profiling identifies biomarkers for immunochemotherapy in esophageal squamous cell carcinoma.",
        "abstract": "Esophageal squamous cell carcinoma ESCC remains highly aggressive malignancy limited therapeutic options immune checkpoint blockade ICB combined chemotherapy improved outcomes resistance mechanism predictive biomarkers poorly understood study aim characterize dynamic change tumor microenvironment TME ICB treatment identify cell population molecular program associated therapeutic response performed scRNAseq scTCRseq scBCRseq 174223 cell 27 sample 22 paired pre posttreatment tumors 2 unpaired tumors 3 adjacent tissues treated neoadjuvant camrelizumab antiPD1 plus chemotherapy ICB treatment reshaped TME increasing CXCL12 inflammatory fibroblast CD1C dendritic cell reducing neutrophil plasma cells Resistanceassociated feature included malignant cell partial epithelialmesenchymal transition pEMT programs DES myofibroblasts FOLR2 macrophages clonally expanded CD8 cell exhibiting terminal exhaustion hand responder harbored RGS13 germinal center B cells study reveals cellular molecular reprogramming TME ICB therapy identifies biomarkers response resistance ESCC insight could potentially guide patient stratification development targeted strategy overcome ICB resistance",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818587/",
        "source_type": "Global"
    },
    {
        "pmid": "40818572",
        "title": "The value of multi-parameters MRI based on amide proton transfer imaging in evaluating the efficacy of concurrent radiochemotherapy for locally advanced cervical cancer.",
        "abstract": "evaluate utility multiparametric magnetic resonance imaging MRI based amide proton transfer APT imaging assessing efficacy concurrent chemoradiotherapy CCRT locally advanced cervical cancer CC retrospectively analyzed clinical imaging data pathologically confirmed CC patient treated hospital January 2020 May 2025 patient underwent conventional MRI APT imaging dynamic contrastenhanced MRI DCEMRI prior treatment Apparent diffusion coefficient ADC values APT values semiquantitative parameter DCEMRI measured Treatment response following CCRT evaluated based Response Evaluation Criteria Solid Tumors RECIST Complete remission CR partial remission PR classified remission group RG stable disease SD progressive disease PD grouped nonremission group NRG Differences APT values ADC values semiquantitative parameter DCEMRI RG NRG analyzed Receiver operating characteristic ROC curve used assess sensitivity specificity area curve AUC APT ADC semiquantitative parameter DCEMRI combination predicting CCRT response Delong test used statistical comparison AUCs total 43 patient included 5 1163  achieving CR 31 7209  achieving PR 5 1163  classified SD 2 465  PD resulting local control rate 9535  APT value RG significantly lower NRG 313  ± 024  vs 336  ± 016  P  002 ADC value significantly higher 089 ± 011 × 10sup3sup mmsup2sups vs 080 ± 007 × 10sup3sup mmsup2sups P  0034 NRG showed significantly higher value washin rate WIR compared RG P  0035 AUC APT differentiating RG NRG higher ADC WIR difference statistically significant P  005 Moreover combined use APT ADC WIR increased AUC 0893 significantly higher WIR alone P  0024 Multiparametric MRI based APT imaging hold promise predicting CCRT outcome locally advanced CC combination APT ADC WIR improves diagnostic accuracy compared individual parameters offering potential noninvasive tool guiding clinical management CCRT",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818572/",
        "source_type": "Global"
    },
    {
        "pmid": "40818568",
        "title": "Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.",
        "abstract": "Peptide vaccine based small peptide segment contain antigenic epitope recognizable immune cells Unlike traditional vaccines include specific antigenic epitope rather entire pathogen proteins recognized internalized processed presented antigenpresenting cells dendritic cells subsequently presented cells triggering immune response Peptidebased vaccines innovative regimen cancer immunotherapy shown potential elicit targetspecific antitumor immune responses however therapeutic efficacy often diminished poor stability rapid clearance circulation low immunogenicity individual variability immune escape recent years significant advancement achieved mechanism action design delivery potent peptidebased cancer vaccine address limitation clinical translation Long peptide vaccine likely induce antigen crosspresentation short peptide vaccines Tumorspecific peptide antigen tumorassociated antigen developed enhance anticancer immunogenicity Incorporation various delivery systems lipid nanoparticles polymers viral vector substantially improve stability peptide antigen circulation Codelivery peptide antigen adjuvant enhances antigen presentation Tcell activation resulting robust immunogenicity efficacious cancer immunotherapy Combination therapy peptide vaccine therapies including chemotherapy radiotherapy immune checkpoint inhibitors targeted therapy also enhances therapeutic outcomes article provides insight cancer peptide vaccines including mechanism action peptide antigen adjuvants discussing challenge opportunities exploring use delivery system improve pharmacokinetics therapeutic efficacy cancer immunotherapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818568/",
        "source_type": "Global"
    },
    {
        "pmid": "40818557",
        "title": "Invisible warriors: the invisible arsenal of nanotechnology against retinoblastoma.",
        "abstract": "Retinoblastoma common kind intraocular cancer children develops mutation RB1 gene normally encourage proliferation retinal cells Preserving vision preventing metastasis requires prompt diagnosis suitable treatment Standard treatment often problems like chance systemic harm drug tolerance poor absorption eyes Recent advance nanomaterialbased drug delivery technique offer great potential addressing issues Pharmaceuticals transported efficiently fewer adverse effects use nanocarriers also increase bioavailability Although innovative formulation make simpler medication penetrate eyes defences continue release pharmaceutical gradual steady manner Nevertheless comprehensive safety biocompatibility regulatory compliance testing must precede implementation nanomedicinebased therapy people Regulatory approval require toxicological investigation inflammation cytotoxicity ocular impact time study explores pathogenesis retinoblastoma pharmaceutical delivery option driven nanotechnology regulatory toxicological consequences Furthermore underscore recent developments challenges potential future development delivery retinoblastoma medication via nanomedicine Precision medicine advanced nanocarriers may improve retinoblastoma therapy outcomes effects patient care",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818557/",
        "source_type": "Global"
    },
    {
        "pmid": "40818548",
        "title": "Cucurbitacin B in cancer: A comprehensive review of its targets and molecular mechanisms.",
        "abstract": "Cancer remains leading cause mortality industrialized nations driving ongoing research effort develop effective less toxic therapeutic approaches Cucurbitacin B CuB tetracyclic triterpene compound abundant Cucurbitaceae family plants garnered significant attention recent year promising therapeutic properties review synthesized current evidence elucidating CuBs molecular target associated anticancer mechanisms analysis delineates 18 target CuB categorized interaction modality covalent binding partner IGF2BP1 GRP78 PCK2 MTCH2 noncovalent interactors including transcription factor STAT3 Notch1 transferase Src PI3K AKT mTOR RAF MEK ERK chaperone Mortalin antioncogene p53 ligase HDM2 RNAbinding protein hnRNPK immune system receptor TLR4 Numerous vitro vivo study demonstrated CuB exerts anticancer effect diverse mechanisms including inhibition cell proliferation metastasis angiogenesis well induction cytoskeleton disruption cell cycle arrest DNA damage apoptosis autophagy ferroptosis pyroptosis epigenetic regulation Moreover CuB improves tumor resistance synergistic anticancer effect chemotherapy drugs comprehensive target landscape analysis provides mechanistic framework developing CuBbased combination therapy structureoptimized derivatives promote development innovative effective cancer treatment strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818548/",
        "source_type": "Global"
    },
    {
        "pmid": "40818525",
        "title": "Perspectives and Motivational Factors Surrounding Decision-Making in Women with Cancer Considering Fertility Preservation.",
        "abstract": "assess perspective patient referred urgent oncofertility consultation influencing whether proceed decline fertility preservation FP online survey conducted newly diagnosed cancer patient August 2021 July 2023 oncofertility consultation Postpubertal people ovaries recent cancer diagnosis referred urgent oncofertility preservation consultation eligible Primary outcome patients experience final treatment decisions secondary outcome included cycle outcomes Overall 67126 532 completed survey met study criteria Median age 28 year old IQR 2936 referral medical 478 3267 surgical 358 2467 oncologist median interval 3 day IQR 26 referral consultation Breast 642 4367 hematological 119 867 cancer common 5567 821 proceeded cryopreservation 3855 691 oocyte cryopreservation 1255 218 embryo cryopreservation 555 91 both planning chemotherapyradiation 4256 75 chose GnRH agonist declined cryopreservation 3 25 chose GnRHa treatment form FP 967 134 chose FP treatment common reason cryopreserving included time complete FP cancer treatment 417 512 delaying cancer treatment 417 512 common motivating factor pursuing FP concern future fertility 724 4258 health care provider advice 482 2858 patient received urgent oncofertility counseling proceeded treatment Common reason declining timing FP delaying oncological treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818525/",
        "source_type": "Global"
    },
    {
        "pmid": "40818522",
        "title": "Anti-breast cancer effects of Pterocarpus soyauxii Taub aqueous extract and its compounds by integrating ADMET, network pharmacology, molecular docking, dynamic simulation, CLC-Pred and pdCSM-Cancer/PPI approaches, and in vitro validation.",
        "abstract": "Breast cancer one common reason woman seek treatment hospitals exceptionally high mortality rate Powder heartwood Pterocarpus soyauxii Taub P soyauxii used department Lékoumou Republic Congo CongoBrazzaville Central Africa treat cancer exploratory study evaluated antibreast cancer effect Pterocarpus soyauxii P soyauxii compound identified LCMS recently published study water extract physicochemical pharmacokinetic toxicological property compound predicted via MolSoft AIDruglab ToxCSM SToPToX databases Network pharmacology conducted target protein breast cancer P soyauxii compound via GeneCards Metascape STRING Cytoscape Mapping signaling pathway involved breast cancer PI3KAKTmTOR pathway performed KEGG pathway constructed PPI network established protein high score selected molecular docking via Biovia Molegro Virtual Docker software cytotoxic proliferationinhibitory capacity breast cancer cell lines well protein involved predicted using CLCPred way2drug pdCSM database vitro assay result indicated compound P soyauxii exhibited low toxicity soluble water 30 absorbable intestine distribution greater 2 Lkg halflife less 4164 hours Network pharmacology molecular docking revealed compound interact MAPK1 CDK2 respective energy lower tamoxifen 8703 molkcal 12566 molkcal pterostilbene linoleic acid compound displayed cytotoxic inhibitory effect proliferation breast cancer cell lines including MCF7 MDAMB453 probability greater 045 minimum GIsub50sub 4 weaker compared tamoxifen Additionally compound exhibited antiestrogenic activity ICsub50sub value less 5 Mole Ki value greater 550 Mole Furthermore aqueous extract P soyauxii reduced viability MDAMB468 MCF7 cell less tamoxifen ICsub50subs 78389 ± 00125 μgmL 58389 ± 0028 μgmL respectively result suggest P soyauxii compound protective effect various type breast cancer inhibiting PI3KAKTmTOR pathway essential cell cycle progression survival cancer cells However vivo experimental validation model remains necessary confirm protective effect breast cancer",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818522/",
        "source_type": "Global"
    },
    {
        "pmid": "40818480",
        "title": "Effectiveness of comprehensive geriatric assessment with extensive patient coaching for improving quality of life in older patients with solid tumours receiving systemic therapy (G-oncoCOACH): a multicentre randomised controlled trial.",
        "abstract": "Comprehensive geriatric assessment CGA demonstrated numerous benefit older patient cancer internationally recommended data needed impact quality life QoL aim GoncoCOACH study evaluate effectiveness CGA QoL older patient solid tumour receiving systemic therapy integrating geriatric team implementing geriatric assessment GAbased recommendation offering extensive patient coaching compared standard care oncology GoncoCOACH study multicentre randomised controlled trial conducted two academic hospital Belgium Patients aged 70 year older solid tumour initiating systemic therapy curative noncurative intent physicianestimated life expectancy least 6 months randomly assigned 11 either control group standard oncology care receiving GAbased recommendation implemented oncology team intervention group receiving GAbased recommendation implemented geriatric team intensive patient coaching masking participants physicians study personnel primary outcome change global health status GHS baseline 6 months measured using EORTC QLQC30 questionnaire ie QoL GHS Linear mixed model used data analysis Exploratory analysis evaluated predictor change QoL GHS trial registered ClinicalTrialsgov NCT04069962 completed Oct 30 2019 Aug 5 2021 217 participant enrolled randomly assigned 212 QoL GHS available baseline 107 control group 105 intervention group Among 212 participants mean age 76·7 years 111 52 female 101 48 male three common tumour type lung cancer 41 19 colorectal cancer 31 15 breast cancer 22 10 mean difference QoL GHS score intervention group control group 6 month 10·9 point 95 CI 3·718·0 p0·0030 favour intervention group confirmed sensitivity analysis Adherence GAbased recommendation higher intervention group 71 65 110 recommendation implemented control group 67 45 148 recommendation implemented Exploratory analysis revealed significant predictor change QoL GHS low baseline QoL GHS high comorbidity GoncoCOACH study show CGA integration geriatric team implementing GAbased recommendation offering extensive patient coaching improves QoL GHS older patient cancer compared standard care oncology Stand Cancer Kom op tegen Kanker",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818480/",
        "source_type": "Global"
    },
    {
        "pmid": "40818476",
        "title": "Advances in the classification and management of idiopathic inflammatory myopathies.",
        "abstract": "Idiopathic inflammatory myopathy group immunemediated disorder characterised multisystem involvement chronic disease course twothirds adult patients Autoantibodies aid identification disease subtypes associated severe complications cancer interstitial lung disease Patients idiopathic inflammatory myopathy need managed multidisciplinary setting Treatment intravenous immunoglobulin efficacious patient refractory dermatomyositis result improvement disease activity skin muscle Numerous randomised controlled trial underway testing potential therapeutic agent hold promise treatment idiopathic inflammatory myopathies advance include identification pathophysiological mechanisms Induction interferon patient dermatomyositis lead upregulation interferonstimulated gene blood skin muscle tissue interferoninduced transcript could yield diagnostic biomarkers biomarkers monitoring disease activity identification potential biomarkers also propelled development therapy targeting interferon pathwayeither upstream using monoclonal autoantibody blocking downstream signalling pathway via JAK inhibitors promising strategy patient refractory disease targeting B cell CD19targeting chimeric antigen receptor Tcell therapy Treatments targeting cell lymphocyte specific Tcell subset also investigation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818476/",
        "source_type": "Global"
    },
    {
        "pmid": "40818459",
        "title": "SOX4-ZIP14-zinc metabolism mediates oncogenesis and suppresses T cell immunity in nasopharyngeal carcinoma.",
        "abstract": "Subtle variation micronutrient tumor microenvironment often coincide tumor progression immune disorders Nevertheless underlying mechanism micronutrients metal ions influence tumorintrinsic property tumorimmune crosstalk remain inadequately characterized Here integrative analysis multicenter singlecell spatial transcriptome sequencing bulk RNA sequencing RNAseq cohort reveals nasopharyngeal carcinoma NPCspecific SRYbox transcription factor 4 SOX4 governs microenvironmental cellular zinc metabolism downstream target SLC39A14 ZIP14 membrane zinc uptake transporter Mechanistically NPC cell enhance zinc uptake activate Wntβcatenin signaling initiate tumor growth creating zincdeficient niche hostile cells Zinc deficiency tumorinfiltrating CD8supsup cell impairs LCK phosphorylation cell receptor TCR signaling compromising effector function study elucidates idea SOX4ZIP14zinc metabolism axis multifactorial effect NPC fostering malignant phenotype NPC suppressing cell response deprivation zinc metabolism",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818459/",
        "source_type": "Global"
    },
    {
        "pmid": "40818457",
        "title": "Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.",
        "abstract": "first stage phase 1b2 trial evaluating effectiveness safety toripalimab irinotecan bevacizumab patient rectal cancer refusing upfront surgery radiation therapy rectum cohort patient T4NanyM0 colon cancer colon cohort deficiency mismatch repair dMMR microsatellite instability MSI trial allows doctorpatient shared decisionmaking process determine whether omit irinotecan bevacizumab optimal surgery timing primary endpoint pathological complete response pCR rate full analysis set FAS perprotocol set PPS 571 95 confidence interval CI 289823 667 349901 respectively colon cohort n  14 750 356955 100 5171000 respectively rectum cohort n  8 disease recurrence occurs PPS grade 45 drugrelated adverse event observed Toripalimab without irinotecan bevacizumab show promising efficacy manageable toxicity dMMRMSI T4NanyM0 colon cancer locally advanced rectal cancer ClinicalTrialsgov NCT04988191",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818457/",
        "source_type": "Global"
    },
    {
        "pmid": "40818455",
        "title": "RNA Pol II inhibition activates cell death independently from the loss of transcription.",
        "abstract": "RNA Pol IImediated transcription essential eukaryotic life Although loss transcription thought universally lethal associated mechanism promoting cell death yet known Here show death following loss RNA Pol II activity result dysregulated gene expression Instead occurs response loss hypophosphorylated form Rbp1 also called RNA Pol IIA Loss RNA Pol IIA exclusively activates apoptosis expression transcriptionally inactive version Rpb1 rescue cell viability Using functional genomics identify mechanism driving lethality following loss RNA Pol IIA call Pol II degradationdependent apoptotic response PDAR Using genetic dependency PDAR identify clinically used drug owe lethality PDARdependent mechanism finding unveil apoptotic signaling response contributes efficacy wide array anticancer therapies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818455/",
        "source_type": "Global"
    },
    {
        "pmid": "40818441",
        "title": "Development and simulation of a SPECT real time dose monitoring system for BNCT: response at the LENA reactor.",
        "abstract": "Boron Neutron Capture Therapy BNCT selectively target tumor cell sparing healthy ones exploiting neutron capture boron10 accumulates cancerous cells ensure therapy properly tuned realtime dose monitoring treatment play fundamental role Single Photon Emission Computed Tomography SPECT imaging system relying 478 keV gamma ray emitted neutron capture reaction can principle detect boron distribution allow 3D reconstruction dose inside patient However neutron interaction element present tissue structure introduce background signals complicating dose evaluation study FLUKA Monte Carlo simulation applied BNCTSPECT oriented detector simulate image reconstruction process simulation conducted irradiating system LENA Laboratorio Energia Nucleare Applicata Pavia compared experimental data Moreover proofofconcept study SPECT acquisition performed different borated samples experimental simulated result good agreement image acquisition detected counting rates simulated projections reconstructed appropriated iterative algorithm show presented system capable distinguishing two separated vial containing boron10 study show presented system hold good promise enhancing precision dose monitoring localization clinical BNCT treatments reason system deployed real BNCT facility evaluate validate performance clinical conditions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818441/",
        "source_type": "Global"
    },
    {
        "pmid": "40818418",
        "title": "The impact of extracellular vesicles on breast cancer metastasis and therapeutics: genetic considerations.",
        "abstract": "Breast cancer significant health problem across world better understanding cellular molecular property microenvironment breast cancer cell reside paramount Breast cancer cell exhibit intricate bilateral interaction tumour microenvironment contribute tumour progression tumour microenvironment comprises host proteins proteoglycans glycoproteins signalling molecules stromal immune cells addition extracellular vesicles Extracellular vesicle encompass range vesicle facilitate celltocell communication signal relay Examples extracellular vesicle include microvesicles exosomes apoptotic bodies categorisation divide extracellular vesicle exosomes ectosomes based biogenesis content extracellular vesicle DNA RNA miRNA proteins glycans lipids content affect tumour microenvironment tumour metastasis progression such review article aim understand content extracellular vesicle promote invasion metastasis context tumour microenvironment implication extracellular vesicle breast cancer therapeutic addressed Finally gene indicated process discussed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818418/",
        "source_type": "Global"
    },
    {
        "pmid": "40818374",
        "title": "Association between Perfluoroalkyl and polyfluoroalkyl substances exposure and hypercholesterolemia among U.S. adults: A cross-sectional study.",
        "abstract": "Perfluoroalkyl polyfluoroalkyl substance PFAS persistent organic pollutants Evidence supporting association PFAS concentration lipid level reported however comprehensive study intricate association PFAS exposure hypercholesterolemia still lacking analyzed data 2292 adult 20152018 National Health Nutrition Examination Survey Multivariate logistic regression weighted quantile sum WQS regression quantile gcomputation Qgcomp Bayesian kernel machine regression BKMR model used assess association single multiple exposure PFAS prevalence hypercholesterolemia among US adults single PFAS exposure analysis multivariate logistic regression analysis result showed exposure lntransformed perfluorohexane sulfonic acid PFHxS perfluorooctanoic acid PFOA perfluorooctane sulfonic acid PFOS significantly positively associated prevalence hypercholesterolemia overall population odds ratio ORsubLnPFHxSsub 120 95  confidence interval CI 105136 ORsubLnPFOAsub 121 95  CI 103141 ORsubLnPFOSsub 118 95  CI 103134 PFAS mixture exposure analysis WQS OR 116 95  CI 100135 Qgcomp OR 117 95  CI 103132 model consistently confirmed positive effect combined exposure multiple PFAS prevalence hypercholesterolemia LnPFHxS main contributor BKMR model positive association trend observed mixture PFAS hypercholesterolemia along interaction among PFAS conclusion study suggests higher PFAS concentration may increase risk hypercholesterolemia US adults however prospective study required demonstrate this",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818374/",
        "source_type": "Global"
    },
    {
        "pmid": "40818364",
        "title": "Maternal and neonatal outcomes following cesarean delivery on maternal request at different parities in China: A prospective cohort study.",
        "abstract": "Cesarean delivery maternal request CDMR associated elevated higher incidence postpartum maternal neonatal complication compared vaginal delivery However notable lack research investigating influence parity maternal neonatal complication linked CDMR particularly within Chinese population prospective cohort study conducted China aim investigate shortterm maternal neonatal complication associated CDMR among lowrisk nulliparous parous populations Methods study cohort consisted 336 women including nulliparous parous second birth first cesarean delivery elected CDMR Comprehensive data regarding maternal neonatal complication collected perioperative period throughout first year postpartum adjusting agerelated factors finding reveal nulliparous experienced higher incidence postoperative complications complication included delayed initiation breastfeeding increased activityrelated pain within 48 hour postsurgery greater frequency PatientControlled Epidural Analgesia PCEA activations higher incidence pruritus mastitis prolonged postoperative hospital stay all P  005 Furthermore risk hospitalization due neonatal jaundice significantly elevated among newborn nulliparous P  005 comparison parous second birth first cesarean delivery nulliparous underwent CDMR exhibited higher incidence shortterm maternal neonatal complications recommended potential maternal neonatal complication associated CDMR carefully evaluated determining mode delivery nulliparous",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818364/",
        "source_type": "Global"
    },
    {
        "pmid": "40818357",
        "title": "Applications of artificial intelligence in liver cancer: A scoping review.",
        "abstract": "review explores application Artificial Intelligence AI managing primary liver cancer focusing recent advancements AI particularly machine learning ML deep learning DL show potential improving screening diagnosis treatment planning efficacy assessment prognosis prediction followupcrucial element given high mortality liver cancer systematic search conducted PubMed Scopus Embase Web Science databases focusing original research published June 2024 AIs clinical application liver cancer Studies relevant lacking clinical evaluation excluded 13122 screened articles 62 selected full review study highlight significant improvement detecting hepatocellular carcinoma intrahepatic cholangiocarcinoma AI DL model show high sensitivity specificity particularly early detection diagnosis AI model using CT MRI data improve precision distinguishing benign malignant lesion multimodal data integration Recent AI model outperform earlier nonneural network versions though gap remains development clinical implementation Many model lack thorough clinical applicability assessment external validation AI integration primary liver cancer management promising requires rigorous development validation practice enhance clinical outcome fully",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818357/",
        "source_type": "Global"
    },
    {
        "pmid": "40818351",
        "title": "Cancer treatment for older adults: Development, optimization, and personalized anti-cancer therapy.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818351/",
        "source_type": "Global"
    },
    {
        "pmid": "40818326",
        "title": "Eliminating intratumoral bacteria with cGAS-STING-activating nanodrug-bacteria biohybrids potentiates cancer immunotherapy.",
        "abstract": "Breast cancer remains leading cause cancerrelated mortality women intratumoral bacteria playing significant role immunosuppression However targeted therapeutic strategy address microbial influence remain underexplored study developed novel nanodrug bacteria biohybrid system LGGPDACuCPT integrated Lactobacillus rhamnosus GG LGG probiotics polydopamine PDA copperirinotecan CuCPT composite potentiate cancer immunotherapy simultaneously eliminating immunosuppressive intratumoral bacteria activating cGASSTING pathway thereby suppressing tumor progression Photothermal therapy PTT mediated PDA enhanced intratumoral bacterial eradication disrupting bacterial membrane promoting intracellular Cusup2sup uptake Cusup2sup ion induced reactive oxygen specie ROS generation Fentonlike reactions effectively killing intratumoral Fusobacterium nucleatum Fn bacteria thereby relieving bacteriuminduced immunosuppressive tumor microenvironment Concurrently acidic tumor microenvironment PTTinduced heating facilitated release CPT which together LGG activated cGASSTING pathway activation triggered robust type interferon production dendritic cell DC maturation cytotoxic lymphocyte CTL infiltration leading effective immunemediated tumor cell clearance Additionally Fn bacterial remnant acted immunostimulatory agents amplifying immune responses synergistic strategy bacterial elimination cGASSTING activation significantly enhanced antitumor immune response inhibited tumor progression providing promising therapeutic approach breast cancer treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818326/",
        "source_type": "Global"
    },
    {
        "pmid": "40818322",
        "title": "Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma.",
        "abstract": "Metabolic reprogramming pancreatic ductal adenocarcinoma PDAC pose significant challenge efficacy gemcitabinebased chemotherapy Aberrant activation intracellular pyrimidine metabolism key factor contributing reduced effectiveness gemcitabine Combining gemcitabine metabolic regulator targeting critical pathway may alleviate gemcitabine resistance study focus abnormal activation dihydroorotate dehydrogenase DHODH PDAC cells pivotal enzyme de novo pyrimidine synthesis pathway diminishes cellular sensitivity gemcitabine catalyzes reduction ubiquinone ubiquinol playing essential role maintaining cellular redox homeostasis address challenges developed GE11 peptidemodified polyphenoliron chelate nanoparticles codelivery long carbon chainmodified gemcitabine DHODH inhibitor leflunomide peptide modification enabling nanoparticles target PDAC cell high expression epidermal growth factor receptor nanoparticles demonstrated ability induce mitocytosis achieve deep tumor penetration PDAC tissues Upon drug release core lesion three components modified gemcitabine leflunomide iron ion synergistically enhanced tumor cell killing alleviating gemcitabine resistance disrupting cellular redox homeostasis induce multimodal cell death situ pancreatic cancer mouse model strategy exhibited superior antitumor efficacy compared standard AG chemotherapy regimen nabpaclitaxel gemcitabine even 63fold lower gemcitabine concentration finding underscore potential approach highly effective therapeutic strategy PDAC treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818322/",
        "source_type": "Global"
    },
    {
        "pmid": "40818319",
        "title": "Why the duration of cancer treatment requires a closer look: An empirical analysis of recent FDA approvals.",
        "abstract": "duration cancer treatment influence efficacy toxicity cost Optimizing duration therapy increasingly recognized need duration planned received therapy FDA registration trial comprehensively studied objective describe FDAapproved cancer drug trial past five years across settings Crosssectional analysis 227 FDA registration trial oncology hematology drug approved January 1 2019 August 19 2024 Data abstracted FDA approval document associated publications main outcome measurement included descriptive statistic triallevel characteristics including treatment duration type fixed v indefinite treatment setting advanced frontline perioperative reported treatment durations Among 227 included trials 136 599  used indefinite course treatment 91 401  used fixed course including 13 singledose trials Among fixed trials 705  planned either 12 24 months median treatment duration received 74 month fixed indefinite trials advancedfrontline fixed trials median difference planned received duration 163 months compared 08 month perioperative trial P  0001 Planned duration treatment recent FDA registration cancer trial often significantly exceed duration patient actually receive trial randomized patient different durations finding underscore need randomized evaluation treatment duration prevent overtreatment Regulators prioritize shorter treatment duration unless strong rationale support longer ones",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818319/",
        "source_type": "Global"
    },
    {
        "pmid": "40818318",
        "title": "A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment.",
        "abstract": "substantial proportion gastric cancer patient develop severe treatmentrelated toxicity significantly impacting healthrelated quality life primary aim study identify distinct toxicity cluster gastric cancer patients secondary aim assess whether cluster membership associated eventfree EFS overall survival OS Patients participated CRITICS trial NCT00407186 included Toxicity first chemotherapy course examined according CTCAE Agglomerative hierarchical cluster modelling used identify patient cluster distinct toxicity profiles Cox proportional hazard analysis performed assess association cluster membership EFS OS 689 788 patient 87  included Four distinct toxicity cluster identified mild toxicity cluster neutropenia cluster poly toxicity cluster gastrointestinal toxicity cluster Patients neutropenia cluster completed preoperative treatment often 95  completion lowest poly toxicity cluster 76  p  0003 Patients neutropenia toxicity cluster longest median OS 58 months patient within gastrointestinal toxicity cluster shortest median OS 22 months p  0005 also observed EFS neutropenia toxicity cluster longest median EFS 44 month compared 13 month gastrointestinal toxicity cluster p  0018 exploratory study identified four distinct toxicity cluster early preoperative chemotherapy gastric cancer patients Cluster membership prognostic EFS OS large difference clusters Patients neutropenia toxicity cluster best EFS OS",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818318/",
        "source_type": "Global"
    },
    {
        "pmid": "40818317",
        "title": "Beyond traditional endpoints: A multi-state modelling approach to integrating morbidity and mortality in cancer treatments evaluation.",
        "abstract": "Traditional benefitharm assessment cancer treatment evaluate morbidity mortality separately overlooking patient experience outcome together study illustrates health profilebased approach using multistate modelling complement assessments compare traditional health profilebased approaches simulated phase 3 trial newly diagnosed glioblastoma traditional analysis estimated median progressionfree survival PFS overall survival OS grade 3 4 G34 toxicity rates health profilebased approach used multistate Markov model MSMM estimate time spent different health state 36 months Qualityadjusted life year QALYs calculated combining timeinstate estimate utility weight simulated reflect patient preference study traditional analysis showed 38month increase median PFS experimental treatment accompanied substantially higher rate G34 toxicity 484  vs 152  allowed balancing benefit harm basis populationlevel effect median PFS cumulative incidence toxicity MSMM approach offered granular view progressiontoxicity tradeoff showing patient experimental group spent less time progressed disease 77 vs 94 months time progressionfree G34 toxicity 38 v 03 months combined simulated individuallevel utility weights QALY value could assigned experimental treatment control Multistate modelling offer flexible way integrate morbidity mortality evaluating cancer treatments capturing health trajectory enabling utilitybased assessments may complement traditional method inform treatment decisions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818317/",
        "source_type": "Global"
    },
    {
        "pmid": "40818316",
        "title": "Hepatic metastases management: A comparative review of surgical resection, thermal ablation, and stereotactic body radiation therapy.",
        "abstract": "Hepatic metastasis contribute significantly cancerrelated mortality across multiple primary malignancies including colorectal melanoma breast lung cancers surgical resection long considered gold standard evolving strategy expanded local treatment options narrative review critically compare three established modalitiessurgical resection thermoablation using radiofrequency RFA microwave ablation MA stereotactic body radiation therapy SBRTthrough lens efficacy limitations clinical applicability Surgical resection remains associated highest 5year overall survival OS rates ranging 25  47  colorectal liver metastasis 65  selected breast cancer cases limited strict eligibility criterion high complication rates Thermoablation minimally invasive option particularly effective lesion  3 cm achieves 5year OS rate 3046  local control LC rate 71  though efficacy reduced near large vessel subcapsular regions SBRT noninvasive imageguided modality enables delivery ablative dos sessions achieves 94  LC 2 year tumor  3 cm remains effective larger lesion modality contraindicated Grade ≥ 3 toxicity rare 10  modern techniques selected cases combining local modalities surgery intraoperative ablation improve LC bilobar borderlineresectable disease Overall three approach viewed complementary tool within multidisciplinary framework allowing tailored treatment strategy patient hepatic metastases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818316/",
        "source_type": "Global"
    },
    {
        "pmid": "40818315",
        "title": "When suboptimal post-protocol care in oncology trials is rewarded.",
        "abstract": "oncology trials overall survival OS remains gold standard endpoint regulatory approval guideline recommendations words strategy survival gain likely favored another However suboptimal postprotocol care  ie control arm patient receive appropriate care protocol  penalize control arm potential artificially drive survival gains Here provide three examples across distinct tumor type  melanoma breast urothelial cancer  distinct setting  perioperative metastatic  inadequate postprotocol care could contributed apparent survival advantages describe current system reward trial either regulatory advantages stronger guideline recommendations both posit postprotocol data become central component trial evaluation particularly interpreting survival outcomes outline practical solutions drug regulation center Presubmission regulatory consultation agency sponsor systematically consider postprotocol care Specifically seek secure optimal treatment patient posttrial observed survival result remain applicable region care standard marketing authorization sought",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818315/",
        "source_type": "Global"
    },
    {
        "pmid": "40818310",
        "title": "Effect of acupressure on management of dyspnea and quality of life in palliative care patients.",
        "abstract": "Management dyspnea important patient diagnosed lung cancer aim study determine effect acupressure dyspnea level quality life palliative care patient dyspnea symptoms randomized controlled experimental study conducted 57 experimental 58 control patient hospitalized palliative care unit May 2023 January 2024 Data collected using Modified Borg Scale MBS FACITPal Functional Assessment Chronic Illness TherapyPalliative care Quality Life Scale study acupressure applied dyspnea acupressure point Lu1 Lu10 P6 3 minutes twice day every day 14 day experimental group Standard care administered control study MBS score patient group compared found MBS score experimental group acupressure application Day 1 4553± 1189 vs 5224±1351 Day 7 3907±1211 vs 5581±1074 Day 14 3048± 973 vs 5357±983 statistically significantly lower control group p0001 addition MBS score experimental group compared acupressure within group Days 1 7 14 determined statistically significant decrease p0001 study found FACTPAL score experimental group higher control group Day 14 137583±13627 vs 123333±10116 p0006 Day 14 respiratory rate experimental group acupressure application statistically significantly lower control group 21365±3652 vs 23166±4477 result study show acupressure reduces vital sign oxygen saturation heart rate respiratory rate systolic diastolic blood pressure dyspnea improves quality life palliative care patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818310/",
        "source_type": "Global"
    },
    {
        "pmid": "40818299",
        "title": "From inert to active: Charge-compensated metallacarboranes with high toxicity and anticancer potential.",
        "abstract": "Since initial synthesis Hawthorne 1960s inorganic metallacarboranes  notably cobalt bisdicarbollide CoSANsupsup considered chemically inert harmless eukaryotic cells reputation inertness supported use wide range biomedical applications including boron source boron neutron capture therapy antifungal Grampositive antibacterial agents superchaotropic membrane carrier impermeable biologically important molecules study report surprising twist newly synthesized iodinated chargecompensated CoSANsupsup derivative boronnitrogen BN bond show promising anticancer activity studied molecule display lownanomolar ICsub50sub value across range human cancer cell lines revealing cytotoxic effect far beyond previously observed class also link activity specific structural motifs identifying auspicious candidate future therapeutic development biological activity evaluated vertebrate vivo model Danio rerio embryos characterize developmental effect toxicological profile best knowledge first demonstration simple CoSANsupsupbased molecule exhibiting high cytotoxic potency cancer cell selectivity finding show subtle chemical modification like incorporating BN bond adjusting charge  unlock powerful bioactivity molecule thought inert opening new possibility unconventional anticancer drug design",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818299/",
        "source_type": "Global"
    },
    {
        "pmid": "40818296",
        "title": "Obesity and gastrointestinal cancer: A converging epidemic with surgical consequence.",
        "abstract": "Obesity recognised carcinogen growing implication gastrointestinal surgical oncology Excess adiposity promotes tumourigenesis endocrine inflammatory mechanical pathways contributing increased cancer incidence stage diagnosis worse oncological outcomes patient undergoing gastrointestinal cancer surgery obesity add significant technical complexity elevates perioperative morbidity effective intervention bariatric surgery GLP1 receptor agonist exist integration cancer care remains limited Emerging evidence suggests potential oncological benefit highquality data perioperative implementation impact treatment response scarce Randomised trial evaluating shortcourse pharmacological strategy neoadjuvant pathway urgently needed interim routine preoperative obesity screening referral structured weight loss embedded multidisciplinary workflows perspective underscore importance recognising addressing obesity comorbidity modifiable risk factor therapeutic target across cancer continuum",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818296/",
        "source_type": "Global"
    },
    {
        "pmid": "40818295",
        "title": "Proposing re-classification of bile duct cancer and intrahepatic cholangiocarcinoma: A suggested modification based on the WHO classification.",
        "abstract": "current definition bile ductderived cancer overly broad ambiguous encompassing malignant tumor arising biliary epithelium throughout intrahepatic biliary tree However lack systematic approach refining carcinoma intrahepatic bile duct cancer CIBDs definition hindered development optimal treatment strategy affected patients address issue conducted comprehensive review World Health Organization WHO Classification Tumors incorporating key consideration anatomical location tumor origin pathological classification biological behavior clinical manifestations therapeutic approaches Based comprehensive analysis propose refined classification system CIBDs believe framework would help standardize unify categorization CIBDs clinical practice",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818295/",
        "source_type": "Global"
    },
    {
        "pmid": "40818284",
        "title": "RAC2 drives hypoxia-mediated radiation resistance in nasopharyngeal carcinoma.",
        "abstract": "Nasopharyngeal carcinoma NPC exhibit unique radiosensitivity yet radioresistance remains major therapeutic challenge study investigates role RAC2 hypoxiainduced radioresistance reactive oxygen specie ROS regulation Radiation effectiveness demonstrated dosedependent DNA damage proliferation inhibition ROS elevation NPC cells hypoxic condition attenuated effects Mechanistically RAC2 identified crucial mediator hypoxiainduced radioresistance modulating NADPH oxidasederived ROS production finding reveal RAC2 drive hypoxiaassociated radioresistance NPC amplifying ROS production suggesting potential therapeutic target radiosensitization research provides new insight overcoming hypoxiamediated radioresistance NPC treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818284/",
        "source_type": "Global"
    },
    {
        "pmid": "40818237",
        "title": "Risk communication during treatment decision-making conversations with older people with advanced kidney disease.",
        "abstract": "older people advanced kidney disease medically ineligible transplant hence treatment available dialysis conservative kidney management CKM Previous research indicates information patient receive clinicians dialysis often prioritised CKM However evidence older people health issues dialysis always beneficial aim investigate whether risk benefit discussed relation option consultations convey CKM valid option Outpatient consultation recorded across four UK renal unit purposively selected variability CKM rate amongst patient age 65 Chronic Kidney Disease data British English total 30 conversation identified concerned decision dialysis CKM 22 led doctor 8 led nurses included 20 conversation option listed undecided patients eight prior decision revisited two recommendation made dialysis Conversations analysed using conversation analysis found CKM treated valid option patient risks burden limited benefit dialysis framed significant term quality andor length life found following aspect clinician communication enabled patient respond way treated CKM valid treatment option 1 talking impact dialysis persons quality life 2 conveying uncertainty regarding potential benefit dialysis length life 3 conveying risk personally relevant patients circumstances Findings demonstrate clinician convey information patient risk dialysis advanced kidney disease enable patient recognise consider CKM valid option",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818237/",
        "source_type": "Global"
    },
    {
        "pmid": "40818216",
        "title": "Development and validation of interpretable machine learning model for pre-treatment predicting the response to targeted and immune therapy in hepatocellular carcinoma.",
        "abstract": "Targeted immune therapy used unresectable hepatocellular carcinoma HCC efficacy limited tumor heterogeneity Identifying patient benefit targeted immune therapy crucial optimizing treatment strategy prognosis aimed develop validate interpretable machine learning ML model integrating clinical CT imaging characteristic pretreatment prediction objective response prognosis targeted immune therapy HCC retrospective multicenter study included 413 patient two institution received targeted immune therapy Clinical CT characteristic collected Logistic Regression LR Support Vector Machine SVM Random Forest RF eXtreme Gradient Boosting XGBoost model developed validated predict treatment response overall survival OS Model performance assessed area curve AUC KaplanMeier analysis Additionally SHAP SHapley Additive exPlanations analysis explained model prediction aggregating attribution value input feature XGBoost model demonstrated best performance AUCs 0802 95  CI 07440860 0805 95  CI 07410868 training validation cohorts Significant predictor included Barcelona Clinic Liver Cancer BCLC stage tumor number tumor margin peritumoral enhancement macrovascular invasion KaplanMeier analysis showed highrisk score stratified XGBoost model associated shorter OS HR 0740 95  CI 06650823 P  0001 XGBoost model effectively predicted treatment response prognosis HCC patient undergoing targeted immune therapy offering noninvasive tool guide treatment decision optimize clinical outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818216/",
        "source_type": "Global"
    },
    {
        "pmid": "40818211",
        "title": "Immune stratification in HPV-negative HNSCC: prognostic significance and prediction of immunotherapy response.",
        "abstract": "tumor immune microenvironment TIME played crucial role head neck squamous cell carcinoma HNSCC significantly impacting disease progression immunotherapy address complexities analyzed gene expression profile 790 HNSCC tumor combining data Cancer Genome Atlas TCGA n  520 Gene Expression Omnibu database GEO n  270 identified five distinct TIMEbased phenotypes E classcharacterized tertiary lymphoid structure TLSshowing highest survival rate immunotherapy responses assess TLS prognostic value evaluated two cohort human papillomavirus HPV infection negative HNSCC 247 surgical resection patient 35 immunotherapytreated patient postoperative recurrencemetastasis Additionally analyzed GEO dataset n  102 comprising HNSCC patient metastasisrecurrence received PD1PDL1 inhibitors integrating clinical transcriptomic data Immune stratification system integrating TIME composition immune cell count revealed TLSpositive patient exhibited superior survival enhanced immunotherapy response HPVnegative HNSCC two immune stratification system exhibited greater accuracy predictive power estimating overall survival HPVnegative HNSCC patient compared use TNM staging tumor pathological stage finding provided framework establishing TLSbased personalized treatment HPVnegative HNSCC potentially enhancing disease surveillance informing clinical practice improving patient prognosis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818211/",
        "source_type": "Global"
    },
    {
        "pmid": "40818210",
        "title": "Transoral robotic surgery in oral tongue cancer patients with trismus: a retrospective evaluation of feasibility and surgical outcomes.",
        "abstract": "Transoral robotic surgery TORS transformed surgical management head neck tumors yet role oral tongue cancer trismus remains underexplored Traditional open approach posterior extensive tongue lesion often associated high morbidity poor aesthetic outcomes study investigates feasibility safety outcome TORS glossectomy oral tongue cancers particularly anatomically challenging case trismus tumor extension adjacent structures retrospective study 67 patient oral tongue cancer underwent TORS glossectomy single surgeon April 2016 December 2024 Patient demographics tumor characteristics operative details postoperative outcome analyzed Comparative analysis performed patient without trismus patient successfully underwent TORS without conversion open surgery Negative surgical margin achieved 985 cases significant difference observed trismus nontrismus group operative time blood loss reconstruction rates functional outcomes Notably TORS enabled adequate exposure even trismus case may inadvertently improved mouth opening fibrotic soft tissue release overall complication rate low patient resumed oral intake within two weeks TORS glossectomy safe effective technique complex oral tongue cancer including patient trismus tumor extension finding support broader adoption TORS minimally invasive alternative traditional open surgery select oral cavity malignancies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818210/",
        "source_type": "Global"
    },
    {
        "pmid": "40818204",
        "title": "A new era in colorectal cancer: Artificial Intelligence at the forefront.",
        "abstract": "Colorectal Cancer CRC third common malignancy second leading cause cancer death globally radiology interlaces various medical fields progress Artificial Intelligence AI radiology impacted diverse area medicine including CRC Utilizing AI Machine Learning ML Deep Learning DL Explainable AI XAI hybrid model CRC screening lead notable decrease occurrence mortality CRC patients Incorporation bioinformatics tool within AI aid screening identifying significant number CRC biomarkers Due demand enormous amount research conducted Therefore study utilized Systematic Literature Review SLR encompass facet finding relevant articles Inspection genetic factor inspection CRC early detection latestage CRC rapid prediction treatment plan selection metastatic biomarkers discovery CRC type classification CRC risk prediction CRC survival rate prediction critical us application employed CRC field Random Forest RF Support Vector Machine SVM Conventional Neural Network CNN AI model frequently used scenarios comprehensive assessment conducted diverse issue obstacle associated implementing AI application particular disease According data paper evaluated mainly accuracy delay time data privacy robustness dataset availability ML model employed 50  papers DL model account 233  Furthermore XAI utilized 10  cases hybrid model implemented 167  papers Inspection genetic factors early CRC detection latestage CRC rapid prediction treatment plan selection metastatic biomarkers discovery CRC type classification CRC risk prediction CRC survival rate prediction highlight critical contribution AI CRC field",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818204/",
        "source_type": "Global"
    },
    {
        "pmid": "40818199",
        "title": "CAR-T for Lung Cancers: Challenges and Innovations.",
        "abstract": "Lung cancer LC leading cause cancer mortality worldwide Despite current therapies including surgery radiotherapy targeted therapies immunotherapy patient experience relapse Immune checkpoint inhibitor ICIs revolutionized LC treatment subset patient benefit them Chimeric antigen receptor CAR cell therapy emerges innovative promising strategy oncology CAR cell genetically modified lymphocyte express chimeric receptor specific tumor antigen promising hematology CAR far struggled transferred clinic solid tumors including LC CAR strategy LC present challenge selection optimal antigen avoid offtarget effects known antigen heterogeneity immunosuppressive environment LC relatively short persistence CAR may encounter disseminated diseases Despite limitations describe growing preclinical clinical study exploring various LC antigen CAR within variety novel approach combinatorial strategy overcome barriers Considering emerging critical mass despite limits expect endeavour translate fraction CAR clinical practice efficacy still deadly LCs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818199/",
        "source_type": "Global"
    },
    {
        "pmid": "40818198",
        "title": "Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer.",
        "abstract": "clinical outcome transformed smallcell lung cancer TSCLC previously considered comparable primary SCLC PSCLC However whether TSCLCs PSCLCs differ era immunotherapy remains unclear Clinical outcome retrospectively analyzed Overall survival OS estimated using KaplanMeier method Cox regression Linear correlation regression analysis used assess prognostic value baseline neuronspecific enolase NSE Hierarchical clustering used group neuroendocrine NE marker TSCLC immunohistochemical results March 2018 March 2023 206 patient TSCLC n  42 PSCLC n  164 enrolled study median OS mOS TSCLC cohort significantly shorter PSCLC cohort 117 vs 129 months P  0033 TSCLC cohort mOS chemoimmunotherapy significantly outlasted chemotherapy 154 vs 85 months P  0001 optimal baseline NSE cutoff value differed TSCLC 197 ngml PSCLC 748 ngml high NSE level associated poorer mOS TSCLC 100 vs 165 months P  0003 PSCLC 108 vs 165 months P  0001 cluster stronger expression NE marker TSCLC exhibited longer mOS 143 vs 103 months P  0030 TSCLC statistically poorer prognosis PSCLC difference modest Chemoimmunotherapy might improve outcome TSCLC Patients TSCLC show stronger neuroendocrine feature may poorer prognosis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818198/",
        "source_type": "Global"
    },
    {
        "pmid": "40818197",
        "title": "Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.",
        "abstract": "Patients withEGFRsensitizing mutation nonsmall cell lung cancer NSCLC predominantly receive firstline tyrosine kinase inhibitor TKIs Subsequent TKI resistance manifest heterogeneous clinicopathological features including distinct resistance subtypes primary vs acquiredPDL1expression levels molecular profile rebiopsies immunotherapy represents potential subsequent option predictive biomarkers guiding optimal patient selection remain undefined multicenter retrospective study analyzed 1396 EGFRmutant NSCLC patient five Chinese institutions 312 meeting stringent inclusion criteria Comprehensive treatment data encompassing EGFRTKIs platinumbased chemotherapy antiangiogenic agents immune checkpoint inhibitor ICIs collected Cox proportional hazard regression identified progressionfree survival PFSassociated variables enabling resistance subtyping Comparative effectiveness analysis across therapeutic modality performed Multivariable Cox regression identified two independent predictor immunotherapy PFSEGFRmutation subtypes exon21 L858R vs exon19del HR 084 95  CI 070099 P  0042 TKI resistance classification acquired vs primary HR 228 95  CI 152343 P  0001 Patients primary TKI resistance showed improved outcome ICIs median PFS 85 vs 40 months HR 04695  CI 029076 P  0002 particularly L858Rmutant subgroups contrast acquired resistance cohortsespecially exon19del mutationsderived limited clinical benefit HR 109 95  CI 084142P  0510 finding suggest resistance subtype mutation profile may aid immunotherapy selection EGFRmutant NSCLC requiring validation prospective studies multicenter analysis demonstrates immunotherapy outcome EGFRmutant NSCLC TKI failure influenced resistance subtypes primary vs acquired specific EGFR mutation profile L858R vs exon19del Patients primary resistance L858R mutation derive clinically meaningful benefit ICIs acquired resistance particularly exon19del variants showed limited efficacy finding support investigation resistancephenotypeguided therapeutic algorithm prospective trial optimize treatment sequencing strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818197/",
        "source_type": "Global"
    },
    {
        "pmid": "40818181",
        "title": "Canagliflozin inhibits hepatic stellate cells activation and proliferation by inhibiting PP2A-mediated β-catenin dephosphorylation to attenuate hepatic fibrosis.",
        "abstract": "Hepatic fibrosis HF leading cause death worldwide yet currently safe effective treatment available Canagliflozin novel glucoselowering drug shown improve nonalcoholic steatohepatitis NASH However therapeutic effect HF underlying molecular mechanism remain unclear study HF induced mouse via intraperitoneal injection CClsub4sub Additionally immortalized hepatic stellate cell HSCs including HSCT6 LX2 cells used vitro experiments finding revealed Canagliflozin inhibited activation proliferation HSCs thereby downregulated expression level fibrotic marker αSMA Collagen I ultimately alleviating HF investigation demonstrated Canagliflozin inhibits protein phosphatase 2 PP2A activity HSCs turn prevents PP2Amediated dephosphorylation βcatenin attenuates Wntβcatenin signaling Wntβcatenin signaling considered key mechanism promote activation proliferation HSCs also crucial pathway development HF Moreover increased activity PP2A found promote expression fibrotic marker αSMA Collagen I HSCs conclusion study indicates Canagliflozin ameliorate HF via inhibiting PP2Amediated dephosphorylation βcatenin HSCs inhibition PP2A HSCs may represent potential therapeutic target cancer treatment also management HF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818181/",
        "source_type": "Global"
    },
    {
        "pmid": "40818177",
        "title": "Exploring social influences on healthcare user decision-making.",
        "abstract": "Commonly used choice model healthcare assume decisionmaking individualistic process individual group ie influencers fact impact decisionmaking purpose study examine different way influencers affect healthcare user decisionmaking important step towards improving choice model healthcare Two focus group n  12 41 semistructured interview conducted within range healthcare domains influenza vaccination birth care joint replacement prostate cancer treatment domains healthcare user physician interviewed Participants recruited collaboration GP hospital research panel Data analyzed grounded theory approach Results reveal three main element decisionmaking affected different social influence mechanisms informationgathering phase perception alternatives attribute level risk influenced information retrieved someone social network others experiences social norms preference formation phase relative importance attribute value alternative impacted social norms advice consideration influencers stake decision Finally process actual decisionmaking could deliberationbased intuitionbased discussion consultation others exact strength impact influence differed per healthcare domain study provides insight social influence healthcare user decisionmaking across multiple healthcare domain provides comparison domains Several connection influencers social influence mechanism choice construct identified finding help choice modeler develop model accurately reflect decisionmaking process health",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818177/",
        "source_type": "Global"
    },
    {
        "pmid": "40818161",
        "title": "In situphotothermal-chemical dynamics synergistic enhancement of anti-tumor effect based on phycocyanin multifunctional nanosystem.",
        "abstract": "Colorectal cancer CRC treatment remains challenged systemic toxicity nonspecific targeting high recurrence rate associated conventional therapeutic approaches study tumor microenvironment TMEactivated multifunctional nanoplatform PDTFCM developed synergistic treatment integrating photothermal therapy PTT chemodynamic therapy CDT chemotherapy CT platform comprises phycocyanin core doxorubicin DOX metalphenolic network shell cloaked CT26 tumor cell membrane homologous targeting acidic TME CRC Fe³supsupreacts endogenous Hsub2subS generate photothermal agent FeS situ thereby activating PTT nearinfrared irradiation Concurrently DOX released enhanced Fenton reaction amplify ROS generation enabling CDTCT synergy vitro experiment showed H₂S depletion ROS overproduction PDTFCM inducing significantly CRC cell apoptosis vivo experiment revealed precise tumor accumulation localized hyperthermia 51°C postirradiation achieving significant tumor growth inhibition without systemic toxicity TMEresponsive multimodal platform PDTFCM present novel synergistic therapy strategy precision CRC treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818161/",
        "source_type": "Global"
    },
    {
        "pmid": "40818141",
        "title": "Dental treatment approaches under general anesthesia in children with cancer.",
        "abstract": "evaluate dental treatment approach general anesthesia child cancer DMFT value existing decay missing filled teeth 68 pediatric patient receiving active cancer treatment recorded Systemic physical examination patient performed paediatrician İntraoral extraoral examination child performed pediatric dentists dental treatment plan encompasses childs individualized oral health needs Dental procedure generally performed controlled environment hospital operating room general anaesthesia Analyzes made SPSS 250 package program study determined average age 647±293 study extractionfocused treatment used instead restorative r0346 p001 endodontic treatment r0274 p001 Despite development restorative endodontic treatment general anaesthesia even pediatric crown applications radical decision must made control medical condition patient childhood cancers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818141/",
        "source_type": "Global"
    },
    {
        "pmid": "40818135",
        "title": "Butyrate enhances recovery of chemotherapy-induced oral mucositis by enhancing tight junction protein expression and inhibiting inflammatory responses.",
        "abstract": "Chemotherapyinduced oral mucositis OM common complication cancer treatment significantly impact patients quality life Butyrate shortchain fatty acid shown inhibit inflammation mitigate intestinal mucosal damage How effect treating OM remains unclear OM model mouse pretreated 5FU solution established injecting 20 acetic acid oral mucosa Sodium butyrate given treatment HE staining used observe histopathological changes qRTPCR assess inflammatory factor level change ulcer tissue treatment Also qRTPCR immunofluorescence staining used evaluate expression distribution tight junction protein ulcer tissues Sodium butyrate treatment improved weight loss mouse caused OM promoted repair oral mucosa timedependent manner addition sodium butyrate significantly inhibited mRNA level inflammatory factor tumor necrosis factorα TNFα interleukin1β IL1β interleukin6 IL6 interleukin18 IL18 ulcer tissue Moreover sodium butyrate promoted mRNA protein expression tight junction protein1 ZO1 Claudin1 epithelial cell ulcer tissue Butyrate promotes OM healing reducing inflammation increasing expression tight junction protein ulcer tissues",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818135/",
        "source_type": "Global"
    },
    {
        "pmid": "40818124",
        "title": "Identification of actin cytoskeleton organization genes in oral cancer and oral potentially malignant disorders using oral tissue RNA-seq database.",
        "abstract": "Oral cancer oral potentially malignant disorder leukoplakia oral submucous fibrosis prevalent clinically significant oral diseases Actin crucial epithelial tissue integrity undergoes cytoskeleton reorganization associated increased invasiveness oral cancer Bioinformatic analysis RNAseq data GEO public database performed detect differentially expressed gene oral cancer leukoplakia oral submucous fibrosis Enrichment analysis differentially expressed gene performed using DAVID GSEA softwares ROC curve survival analysis conducted assess discriminative capacity gene possible biomarkers result validated using RNAseq data Cancer Genome Atlas TCGA EPRS1 consistently overexpressed three pathologies Key gene ACTIN1 LIMK1 CORO1C INF2 SH3D21 CFL1 FSCN1 MYO1B implicated actin cytoskeleton organization identified suggesting role oral potentially malignant disorder cancer progression Receiver operating characteristic ROC curve 522 TCGA sample demonstrated genes potential early biomarkers oral cancer inhibition associated improved survival identified gene offer insight actinrelated mechanism potential pathway diagnosis treatment oral cancer Nonetheless research essential validate results",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818124/",
        "source_type": "Global"
    },
    {
        "pmid": "40818120",
        "title": "Biomarkers in oral squamous cell carcinoma: a systematic review.",
        "abstract": "Oral squamous cell carcinoma OSCC one aggressive cancer oral cavity often diagnosed advanced stages leading significantly reduced survival rates Traditional diagnostic methods clinical examination histopathology limitation detecting early stage assessing tumor variability Molecular biomarkers however shown great potential overcoming limitation improving early diagnosis prognosis personalized treatment biomarkers integrated TNM staging system may provide accurate personalized clinical management systematic review conducted searching PubMed Scopus Web Science database study biomarkers OSCC published January 2018 December 2024 study selected based strict inclusion exclusion criteria focusing investigated biomarkers related OSCC diagnosis prognosis therapeutic implications review includes 10 study involving 1024 patient OSCC Key biomarkers Ki67 HSP60 Survivin Ecadherin PDL1 significantly associated tumor progression lymph node metastasis poor prognosis combined use biomarkers traditional histopathological method could enhance diagnostic accuracy allowing better patient stratification targeted treatment approaches Additionally salivabased biomarkers emerged promising noninvasive diagnostic tool high sensitivity specificity early detection OSCC identification specific biomarkers significantly enrich diagnostic prognostic therapeutic management OSCC complementing TNM staging system biomarkers linked critical clinical variable metastasis survival response treatment Salivabased biomarkers hold promise due noninvasive nature validation multicenter study standardization required widespread clinical adoption",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818120/",
        "source_type": "Global"
    },
    {
        "pmid": "40818108",
        "title": "The Effect of α-Mangostin on the Pharmacokinetic Profile of Tofacitinib in Rats Both In Vitro and In Vivo.",
        "abstract": "study investigated effect αmangostin αMG pharmacokinetics tofacitinib vitro vivo aiming recommend appropriate application clinical practice investigate value ICsub50sub inhibition αMG vitro rat liver microsome incubated tofacitinib study SpragueDawley rat randomly assigned three groups control group singledose group 50 mgkg αMG multipledose group 50 mgkgd αMG 7 days Tofacitinib 10 mgkg administered 30 min intervention αMG group plasma collected caudal vein different time point heparinized tubes Tofacitinib metabolite plasma determined UPLCMSMS analysis conducted utilizing Pymol molecular docking simulation evaluate effect αMG tofacitinib result showed MG inhibited metabolism tofacitinib vitro exhibiting competitive noncompetitive inhibition importantly found multipledose administration αMG significantly increased AUCsub012hsub AUCsub0∞sub Csubmaxsub prolonged tsub12sub shortened MRTsub012hsub MRTsub0∞sub tofacitinib time CLsubzFsub decreased consistent result vitro experiments Furthermore observed significant difference singledose multipledose groups Intriguingly αMG tofacitinib close CYP3A4 spatial location summary investigation demonstrated αMG significantly impact metabolism tofacitinib vitro vivo suggesting potential herbdrug interaction HDIs use tofacitinib herb containing MG monitored clinically",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818108/",
        "source_type": "Global"
    },
    {
        "pmid": "40818090",
        "title": "Machine Learning Approach Identifies miRNA Biomarkers for Post Surgical Patient Stratification in Prostate Cancer.",
        "abstract": "Effective management postprostate cancer hindered limitation current prognostic tool accurately assessing disease aggressiveness Radical prostatectomy remains standard treatment patient develop biochemical recurrence metastasis underscoring need improved postsurgical prognostic tools investigation involved sequencing data derived 38 matched prostate cancer patient undergone RP Initial statistical analysis helped identify significant miRNAs subjected unsupervised clustering stepwise selection linear discriminant analysis LDA model trained tested using miRNA combination method pinpoint biomarkers predictive metastasis 1123 miRNAs initially identified 519 selected highconfidence candidates Parametric analysis miRNAs discerned 41 effectively distinguished patient developed metastasis postoperatively not Utilizing LDA study harnessed 41 miRNAs combinatorial approach identifying eight key miRNAs hsamiR106b3p hsamiR7695p hsamiR1825p hsamiR1945p hsamiR3455p hsamiR1833p hsamiR200a3p hsamiR301a3p collectively stratified metastatic group control 91 accuracy models effectiveness supported receiver operating characteristic analysis demonstrating area curve 80 higher best miRNA combinations Notably performance eightmiRNA panel consistent CAPRAbased risk stratification study present miRNAbased machine learning model distinguishes metastatic nonmetastatic prostate cancer patient following surgery panels alignment CAPRA underscore clinical relevance highlight potential integration future clinical frameworks",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818090/",
        "source_type": "Global"
    },
    {
        "pmid": "40818076",
        "title": "Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) for the treatment of hepatocellular carcinoma.",
        "abstract": "DBIACBP diazepam binding inhibitor acylCoA binding protein major macroautophagyautophagyrepressive protein emerging key player hepatocellular carcinoma HCC pathogenesis multifaceted role encompass cellintrinsic extrinsic mechanisms Beyond promoting cancer cell proliferation DBIACBP contributes protumorigenic microenvironment sustaining inflammation impairing immunosurveillance Experimental model HCC whether induced oncogenes hepatotoxins diet consistently reveal hepatocytespecific knockout iDBIi systemic mutation DBIACBP receptor GABRG2 gammaaminobutyric acid type receptor subunit gamma2 antibodymediated neutralization DBIACBP attenuates tumor growth Mechanistically DBIACBP inhibition reduces fibrogenesis accumulation immunosuppressive Tcell subtypes enhancing antitumor immune response context PDCD1PD1 blockade Simultaneously DBIACBP inhibition increase expression proferroptotic gene protein decreasing antiferroptotic liver thereby sensitizing HCC cell ferroptosis form cell death associated autophagy Clinically elevated iDBIi mRNA expression tumor circulating DBIACBP protein correlate poor prognosis HCC patients Hence targeting DBIACBP offer promising strategy disrupt metabolic inflammatory immunosuppressive network driving HCC progression",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818076/",
        "source_type": "Global"
    },
    {
        "pmid": "40818045",
        "title": "A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.",
        "abstract": "study evaluated efficacy safety intrapleural perfusion methotrexateloaded tumor cellderived microparticles MTXTMPs combined systemic therapy ST patient malignant pleural effusion MPE secondary lung breast cancer multicenter randomized openlabel trial 102 patient assigned 11 receive either MTXTMPs intrapleural perfusion 50 mL daily 4 days plus ST cohort 1 interleukin2 IL2 intrapleural perfusion 50 mL every 3 day three sessions plus ST cohort 2 objective response rate ORR disease control rate DCR pleural effusion evaluated 91 patient 50 cohort 1 41 cohort 2 ORR significantly higher cohort 1 cohort 2 760 vs 537 p  0025 DCR 920 vs 707 p  0012 Among 83 patient included survival analysis median overall survival OS 150 month 95 CI 92269 cohort 1 69 month 95 CI 53158 cohort 2 HR  075 95 CI 046124 p  0266 One two threeyear OS rate cohort 1 553 362 255 compared 389 250 250 cohort 2 regimen showed manageable safety profiles anemia pyrexia fatigue leukopenia gastrointestinal symptoms liver dysfunction common treatmentrelated adverse events finding suggest intrapleural perfusion MTXTMPs combined ST represents promising safe strategy management MPE patient lung breast cancer",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818045/",
        "source_type": "Global"
    },
    {
        "pmid": "40818044",
        "title": "Advances in the management of ovarian cancer liver metastasis.",
        "abstract": "Liver metastasis represents critical challenge cancer progression particularly complex therapeutic implications ovarian cancer patients ovarian cancer liver metastasis OCLM mark distinct stage disease progression demand specialized diagnostic therapeutic approaches Despite clinical significance guidance OCLM management remains notably absent current clinical practice comprehensive review synthesizes recent advance management OCLM special emphasis resectabilitybased classification system",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818044/",
        "source_type": "Global"
    },
    {
        "pmid": "40818009",
        "title": "FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety.",
        "abstract": "Pancreatic cancer among lethal malignancies limited realworld data comparing frontline chemotherapy regimen across disease stages FOLFIRINOX gemcitabine plus nabpaclitaxel G  P standard treatment differing toxicity profile outcomes study evaluated comparative efficacy safety regimen metastatic locally advanced LAPC borderline resectable pancreatic cancer BRPC conducted retrospective study 150 patient treated October 2019 November 2023 tertiary center India Patients received FOLFIRINOX n  64 G  P n  86 firstline therapy Subgroup size included metastatic n  89 LAPC n  34 BRPC n  27 Outcomes assessed included progressionfree survival PFS overall survival OS eventfree survival EFS response rates resectability toxicities KaplanMeier analysis Cox regression used Subgroup analysis stratified stage CA 199 levels metastatic disease median OS 11 month FOLFIRINOX vs 10 month G  P HR  126 p  038 PFS 6 month groups LAPC OS 155 vs 17 month p  084 BRPC FOLFIRINOX showed superior OS 37 vs 16 months p  002 higher surgical conversion 66 vs 39 Grade ≥ 3 toxicity occurred 45 FOLFIRINOX vs 21 G  P Elevated CA 199  37 UmL independently predicted worse OS HR  172 p  0029 FOLFIRINOX G  P comparable efficacy metastatic locally advanced pancreatic cancer FOLFIRINOX offer survival benefit BRPC higher toxicity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818009/",
        "source_type": "Global"
    },
    {
        "pmid": "40818005",
        "title": "A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer.",
        "abstract": "identify molecular cluster develop novel prognostic risk score associated resistance docetaxel chemotherapy predicting biochemical recurrence free survival BCRFS tumor immune microenvironment prostate cancer PCa obtained clinical transcriptome data PCa TCGA GEO database Univariate multivariate Cox regression analysis used establish novel prognostic risk score associated resistance docetaxel chemotherapy predicting BCRFS evaluate validity risk score internal external validation carried out Preliminary invivo invitro experimental validation performed verify biological function NOG PCa docetaxel resistance screening 67 docetaxel resistance related differentially expressed gene DEGs identified three docetaxel resistancerelated cluster significantly different BCRFS immune cell infiltration PDL1 expression importantly novel docetaxel resistancerelated prognostic risk score constructed training testing validating cohorts BCRFS patient highrisk score considerably lower AUCs three cohort 0767 0714 0719 respectively Subgroup analysis suggested risk score strong clinical value TIIIIV N0 cluster 12 PCa patients expression NOG significantly elevated docetaxelresistant PCa cell compared normal strain knockdown NOG reduced IC50 docetaxel docetaxelresistant PCa cell overexpression NOG increased IC50 docetaxel promoted colony formation ability docetaxel treatment DU145 PC3 cells vivo tumorigenesis assay revealed overexpression NOG could promote tumorigenesis PCa docetaxel treatment successfully identified total 67 docetaxel resistance related DEGs novel prognostic risk score associated resistance docetaxel chemotherapy PCa developed validated performed well predicting BCRFS PCa High expression NOG could promote docetaxel resistance PCa",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818005/",
        "source_type": "Global"
    },
    {
        "pmid": "40817986",
        "title": "Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.",
        "abstract": "Triplenegative breast cancer TNBCs associated high frequency PTEN loss lead activation mTOR pathway tumor proliferation may reversible mTOR inhibitor everolimus prior phase II singlearm trial carboplatin everolimus patient advanced TNBC demonstrated good tolerability preliminary efficacy phase II randomized trial patient advanced TNBC 03 prior line therapy conducted Patients randomized 21 receive carboplatin everolimus carboplatin alone primary endpoint progressionfree survival PFS Secondary endpoint included overall survival OS overall response rate ORR clinical benefit rate CBR safety 2015 2022 59 patient randomized carboplatineverolimus n  38 carboplatin alone n  21 median age population 62 year 68 received least one prior line therapy Median PFS significantly improved patient received carboplatineverolimus 47 months versus carboplatin alone 42 months HR049 95 CI 025098 p  00390 OS 176 month combination 146 month carboplatin alone HR117 95 CI 059230 p  06593 common adverse event AEs combination included thrombocytopenia anemia leukopenia neutropenia combination carboplatin everolimus study reduced risk progression death 52 regimen well tolerated provides promising treatment option patient advanced TNBC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817986/",
        "source_type": "Global"
    },
    {
        "pmid": "40817985",
        "title": "Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer.",
        "abstract": "Metastatic breast cancer MBC incurable despite therapeutic advances especially hormone receptor positive HR human epidermal growth factor2 negative HER2 disease Specialist palliative care SPC recommended alleviate distress reduce overly aggressive endoflife EoL care study determined rate SPC hospice utilization aggressive EoL care patient HRHER2 MBC retrospective review performed patient treatment naïve HRHER2 MBC treated endocrine therapy andor cyclindependent kinase 4 6 inhibitor Duke Cancer Institute January 2012 December 2017 Variables pertaining SPC hospice use EoL care outcome March 2024 collected SPC hospice utilization EoL care data analyzed descriptive statistics 102 patients 85 died study period half 55 received aggressive EoL care Half form SPC rate aggressive EoL care comparable engaged SPC not common indicator aggressive EoL care included multiple ED visit 28 hospital admission 23 last 30 day life well inhospital location death 24 Although 72 enrolled hospice care 9 patient hospice ≤ 3 days realworld study demonstrates many patient HR  HER2 MBC receive aggressive EoL care despite engaging SPC many enrolling hospice Interventions decrease aggressive EoL care needed population",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817985/",
        "source_type": "Global"
    },
    {
        "pmid": "40817978",
        "title": "The multifaceted role of KIF15 in cancer progression and therapy.",
        "abstract": "Kinesin family member 15 KIF15 kinesin superfamily motor protein known involved mitotic spindle formation chromosome movement cell division Recent research determined KIF15 crucial regulator several oncogenic pathway proposed role may extend beyond mere cell mechanics Aberrant KIF15 expression also found involved onset numerous cancer promoting proliferation migration invasive ability cancer cells thereby leading increased metastatic capability review summarizes knowledge complex role KIF15 cancer biology highlighting regulatory function interaction key signaling pathway control cell cycle kinetics mechanism tumorigenesis Moreover elevated level KIF15 certain type cancer make amenable target therapy New direction toward inhibiting activity reducing level KIF15 promise restrict tumor growth offering new hope cancer treatment combined understanding KIF15 function stress importance fundamental process cell division also developing field cancer treatment highlighting ongoing necessity extensive research creating effective treatment targeted KIF15 oncology",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817978/",
        "source_type": "Global"
    },
    {
        "pmid": "40817962",
        "title": "Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion.",
        "abstract": "Fibroblast growth factor receptor FGFR2 rearrangement define distinct molecular subset intrahepatic cholangiocarcinoma iCCA therapeutic potential using FGFR inhibitors However acquired resistance invariably limit longterm efficacy posing significant clinical challenge Sequential targeting different FGFR inhibitor emerging strategy yet robust evidence particularly thirdline beyond scarce consensus optimal sequencing patient selection remains unreached Here report case FGFR2rearranged iCCA patient achieved radiographic partial response PR tasurgratinib a thirdline FGFR inhibitor following prior progression pemigatinib futibatinib case underscore sustained dependency FGFR pathway highlight potential clinical utility rationally sequenced FGFRtargeted therapy even multiple line treatment broadly report serf basis current opinion evolving landscape sequential FGFR inhibition iCCA delve complexity acquired resistance dissect argument prolonged FGFR pathway blockade explore impact cooccurring genomic alterations discus controversies research priorities urgent need balanced perspective guide future clinical practice trial design rapidly advancing still uncertain field",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817962/",
        "source_type": "Global"
    },
    {
        "pmid": "40817951",
        "title": "Mediating effects of sense of coherence and psychological resilience on stigma and quality of life among postoperative middle-aged and older patients with malignant gynecological tumors: a cross-sectional, structural equation model.",
        "abstract": "Middleaged older individual crucial stage aging marked increased vulnerability psychological physiological challenges Cancer negative impact quality life patients Stigma closely related quality life QoL middleaged older patient malignant gynecological tumors mechanism behind relationship still unclear Sense coherence SOC psychological resilience PR positive mental health factor alleviate psychological stress improve quality life Therefore study aimed explore mediating role sense coherence psychological resilience stigma quality life crosssectional survey conducted May 2023 January 2024 involving total 428 postoperative patient gynecological oncology department four tertiary grade hospital Fujian Province Assessment tool included Functional Assessment Cancer TherapyGeneral scale Social Impact Scale ConnorDavidson Resilience Scale Sense Coherence Scale13 Data analysis performed using IBM SPSS 260 AMOS 240 software Descriptive analysis showed generally low quality life levels Stigma negatively affected psychological resilience quality life psychological resilience positively affected quality life Stigma also negatively influenced sense coherence whereas sense coherence positively affected quality life Furthermore sense coherence positive effect psychological resilience sense coherence psychological resilience partially mediated relationship stigma quality life Stigma direct impact quality life also exerts indirect effect mediation sense coherence psychological resilience Clinical healthcare provider improve patients quality life reducing stigma promoting sense coherence psychological resilience",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817951/",
        "source_type": "Global"
    },
    {
        "pmid": "40817946",
        "title": "Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.",
        "abstract": "study examines effectiveness platinumbased anthracyclinefree neoadjuvant chemotherapy NAC combined taxanes treating triplenegative breast cancer TNBC Studies published January 2025 systematically retrieved PubMed Web Science Embase Cochrane Library pooled analysis conducted assess pathological complete response pCR rate adverse event AEs survival outcomes Subgroup analysis performed examine influence different chemotherapy regimen patient characteristic treatment efficacy total 30 study involving 3637 TNBC patient included analysis pooled overall survival OS rate 6992 95 confidence interval CI 41658833 2year 3year 5year OS rate 9538 95 CI 86649850 9463 95 CI 87919771 8697 95 CI 80769139 respectively Among secondary outcomes pooled diseasefree survival DFS rate 7753 95 CI 69548391 pCR rate 4645 95 CI 42555039 frequently reported hematologic AEs included anemia neutropenia leukopenia common nonhematologic AEs nausea vomiting along elevation alanine aminotransferase ALT aspartate aminotransferase AST Subgroup analysis demonstrated combination docetaxel carboplatin achieved higher pCR rate 5200 compared paclitaxel plus carboplatin 4200 Concerning geographic origin highest pCR rate observed patient United States 5000 followed Germany 4600 China 4000 term OS highest survival rate reported paclitaxel plus lobaplatin 9400 followed carboplatin 8000 cisplatin 4500 Platinumbased anthracyclinefree NAC regimen combined taxanes appear effective welltolerated patient TNBC Nevertheless absence randomized controlled trial RCTs directly comparing approach anthracyclinebased regimens investigation warranted substantiate findings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817946/",
        "source_type": "Global"
    },
    {
        "pmid": "40817935",
        "title": "Longitudinal changes in delirium motor subtypes among patients with advanced cancer in inpatient hospice and palliative care units: A secondary analysis of a multicenter cohort study.",
        "abstract": "stability delirium motor subtypes palliative care unknown examined longitudinal change delirium motor subtypes palliative care unit stay performed secondary analysis multicenter observational study involving patient advanced cancer assessed delirium motor subtypes symptom including agitation Memorial Delirium Assessment Scale MDAS item 9 communication capacity Communication Capacity Scale CCS item 4 admission T0 day Palliative Performance Scale decline 20 T1 immediately death daily death obtained 9251 delirium assessment 1633 patients 31 experienced hypoactive delirium without hyperactive delirium 35 experienced hyperactive mixed delirium stay stability 57 patient hypoactive delirium 57 hyperactive mixed delirium T0 remained subtype death Further 17 patient hypoactive delirium T0 developed hyperactive mixed delirium stay Moreover 47 patient assessed T0 T1 CCS item 4  3 maintained communication capacity MDAS item 9  2 no moderatetosevere agitation T1 Patients delirium hyperactive mixed hypoactive T0 less likely maintain communication capacity without moderatetosevere agitation T1 patient without delirium T0 adjusting covariates Considering stability delirium motor subtypes difficulty balancing comfort communication palliative care individualized delirium management goal discussed caregivers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817935/",
        "source_type": "Global"
    },
    {
        "pmid": "40817894",
        "title": "Major Adverse Events with Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation.",
        "abstract": "continued advance targeted cancer treatment chimeric antigen receptor Tcell CART therapy emergency department EDs across United States prepared diagnose care patient experience unique adverse event related CART administration CART therapy first genetically modified cellular therapy approved Food Drug Administration treatment several hematologic malignancies including leukemia lymphoma myeloma side effect profile differs conventional chemotherapy consists spectrum immunemediated clinical manifestations particularly cytokine release syndrome immune effector cellassociated neurotoxicity syndrome recently described immune effector cellassociated hemophagocytic lymphohistiocytosislike syndrome Cytokine release syndrome immune effector cellassociated neurotoxicity syndrome immune effector cellassociated hemophagocytic lymphohistiocytosislike syndrome present nonspecific symptom sign differentiated lifethreatening pathology sepsis meningitis limited guidance emergency physician staff regarding recognition management CART complications adult pediatric patient care settings clinical review provides insight common less common CART toxicities including symptomatology diagnostic approach fundamental principle complication management adult pediatric patient undergoing CART therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817894/",
        "source_type": "Global"
    }
]